TCI CO., LTD. AND SUBSIDIARIES

CONSOLIDATED FINANCIAL STATEMENTS AND INDEPENDENT AUDITORS' REVIEW REPORT

SEPTEMBER 30, 2025 AND 2024

For the convenience of readers and for information purpose only, the auditors' report and the accompanying financial statements have been translated into English from the original Chinese version prepared and used in the Republic of China. In the event of any discrepancy between the English version and the original Chinese version or any differences in the interpretation of the two versions, the Chinese-language auditors' report and financial statements shall prevail.

INDEPENDENT AUDITORS' REVIEW REPORT TRANSLATED FROM CHINESE

To the Board of Directors and Shareholders of TCI CO., LTD.

Introduction

We have reviewed the accompanying consolidated balance sheets of TCI CO., LTD. and subsidiaries (the "Group") as at September 30, 2025 and 2024, and the related consolidated statements of comprehensive income for the three months and nine months then ended, as well as the statements, of changes in equity and of cash flows for the nine months then ended, and notes to the consolidated financial statements, including a summary of material accounting policies. Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34, "Interim Financial Reporting" that came into effect as endorsed by the Financial Supervisory Commission. Our responsibility is to express a conclusion on these consolidated financial statements based on our reviews.

Scope of Review

We conducted our reviews in accordance with the Standard on Review Engagements 2410, "Review of Financial Information Performed by the Independent Auditor of the Entity" of the Republic of China. A review of consolidated financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our reviews, nothing has come to our attention that causes us to believe that the accompanying consolidated financial statements do not present fairly, in all material respects, the consolidated financial position of the Group as at September 30, 2025 and 2024, and of its consolidated financial performance for the three months and nine months then ended and its consolidated cash flows for the nine months then ended in accordance with Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34, "Interim Financial Reporting" that came into effect as endorsed by the Financial Supervisory Commission.

Chih, Ping-Chiun　　Tu, Chan-Yuan

For and on behalf of PricewaterhouseCoopers, Taiwan

November 11, 2025

The accompanying consolidated financial statements are not intended to present the financial position and results of operations and cash flows in accordance with accounting principles generally accepted in countries and jurisdictions other than the Republic of China. The standards, procedures and practices in the Republic of China governing the audit of such financial statements may differ from those generally accepted in countries and jurisdictions other than the Republic of China. Accordingly, the accompanying consolidated financial statements and independent auditors' report are not intended for use by those who are not informed about the accounting principles or auditing standards generally accepted in the Republic of China, and their applications in practice.

As the financial statements are the responsibility of the management, PricewaterhouseCoopers cannot accept any liability for the use of, or reliance on, the English translation or for any errors or misunderstandings that may derive from the translation.

TCI CO., LTD. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
SEPTEMBER 30, 2025, DECEMBER 31, 2024 AND SEPTEMBER 30, 2024
(Expressed in thousands of New Taiwan dollars)

	Assets	Notes	September 30, 2025 AMOUNT	%	December 31, 2024 AMOUNT	%	September 30, 2024 AMOUNT	%
	Current assets							
1100	Cash and cash equivalents	6(1)	$ 5,504,143	41	$ 4,767,212	35	$ 4,650,147	34
1110	Financial assets at fair value through profit or loss - current	6(2)	13,005	-	31,014	-	38,832	-
1136	Current financial assets at amortized cost	6(4) and 8	263,320	2	865,166	6	670,996	5
1150	Notes receivable, net	6(5)	24,519	-	81,031	1	17,091	-
1170	Accounts receivable, net	6(5)	941,470	7	776,416	6	891,264	7
1180	Accounts receivable - related parties	7	6,752	-	48,828	1	2,714	-
1200	Other receivables		25,952	-	39,308	-	40,351	-
1210	Other receivables - related parties	7	44	-	104	-	90	-
130X	Inventories	6(6)	757,185	6	855,908	6	959,202	7
1410	Prepayments		219,140	2	168,115	1	186,367	2
1470	Other current assets		53,218	-	48,834	-	34,653	-
11XX	**Total current assets**		7,808,748	58	7,681,936	56	7,491,707	55
	Non-current assets							
1517	Non-current financial assets at fair value through other comprehensive income	6(3)	63,525	1	67,524	-	62,060	-
1550	Investments accounted for using equity method	6(7)	34,391	-	28,182	-	33,604	-
1600	Property, plant and equipment	6(8) and 8	4,625,812	34	4,814,920	35	4,693,954	35
1755	Right-of-use assets	6(9)	190,385	1	236,386	2	257,015	2
1780	Intangible assets	6(10)	610,680	5	643,021	5	655,041	5
1840	Deferred income tax assets		27,312	-	24,799	-	29,647	-
1900	Other non-current assets		195,795	1	217,977	2	349,665	3
15XX	**Total non-current assets**		5,747,900	42	6,032,809	44	6,080,986	45
1XXX	**Total assets**		$ 13,556,648	100	$ 13,714,745	100	$ 13,572,693	100

(Continued)

TCI CO., LTD. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
SEPTEMBER 30, 2025, DECEMBER 31, 2024 AND SEPTEMBER 30, 2024
(Expressed in thousands of New Taiwan dollars)

	Liabilities and Equity	Notes	September 30, 2025 AMOUNT	%	December 31, 2024 AMOUNT	%	September 30, 2024 AMOUNT	%
	Current liabilities							
2100	Short-term borrowings	6(12)	$ 1,512,520	11	$ 429,888	3	$ 504,208	4
2120	Financial liabilities at fair value through profit or loss - current	6(13)	1,136	-	-	-	-	-
2130	Current contract liabilities	6(22)	405,282	3	552,566	4	583,312	4
2150	Notes payable		3,897	-	1,518	-	2,874	-
2170	Accounts payable		650,695	5	679,654	5	658,684	5
2180	Accounts payable - related parties	7	-	-	-	-	152	-
2200	Other payables	6(14)	780,150	6	706,381	5	798,445	6
2220	Other payables - related parties	7	287	-	-	-	-	-
2230	Current income tax liabilities		128,869	1	252,049	2	221,120	2
2280	Current lease liabilities		60,694	-	66,968	-	68,984	-
2320	Long-term liabilities, current portion	6(16)	80,275	-	79,469	1	79,203	1
2399	Other current liabilities, others		106,358	1	136,502	1	142,532	1
21XX	**Total current liabilities**		3,730,163	27	2,904,995	21	3,059,514	23
	Non-current liabilities							
2540	Long-term borrowings	6(16)	1,008,772	7	1,089,529	8	1,109,496	8
2570	Deferred income tax liabilities		69,170	1	82,440	1	85,769	1
2580	Non-current lease liabilities		110,407	1	149,043	1	167,208	1
2600	Other non-current liabilities		6,968	-	562	-	562	-
25XX	**Total non-current liabilities**		1,195,317	9	1,321,574	10	1,363,035	10
2XXX	**Total liabilities**		4,925,480	36	4,226,569	31	4,422,549	33
	Equity attributable to owners of parent							
	Share capital	6(18)						
3110	Share capital - common stock		1,177,288	9	1,182,608	8	1,182,608	9
	Capital surplus	6(19)						
3200	Capital surplus		2,503,467	18	2,893,400	22	2,902,802	22
	Retained earnings	6(20)						
3310	Legal reserve		1,145,367	8	1,060,208	8	1,060,208	8
3320	Special reserve		229,943	2	298,894	2	298,894	2
3350	Unappropriated retained earnings		3,015,272	22	3,324,916	24	3,034,939	22
	Other equity interest	6(21)						
3400	Other equity interest		(347,263)	(2)	(153,980)	(1)	(122,054)	(1)
3500	Treasury shares	6(18)	(434,194)	(3)	(509,948)	(4)	(494,433)	(4)
31XX	**Equity attributable to owners of the parent**		7,289,880	54	8,096,098	59	7,862,964	58
36XX	Non-controlling interest		1,341,288	10	1,392,078	10	1,287,180	9
3XXX	**Total equity**		8,631,168	64	9,488,176	69	9,150,144	67
	Significant contingent liabilities and unrecognized contract commitments	9						
3X2X	**Total liabilities and equity**		$ 13,556,648	100	$ 13,714,745	100	$ 13,572,693	100

The accompanying notes are an integral part of these consolidated financial statements.

TCI CO., LTD. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
THREE MONTHS AND NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024
(Expressed in thousands of New Taiwan dollars, except earnings per share amounts)

			Three months ended September 30				Nine months ended September 30			
			2025		2024		2025		2024	
	Items	Notes	AMOUNT	%	AMOUNT	%	AMOUNT	%	AMOUNT	%
4000	Sales revenue	6(22) and 7	$ 1,740,037	100	$ 1,804,527	100	$ 5,123,227	100	$ 5,293,839	100
5000	Operating costs	6(6)(15)(27)(28) and 7	(971,115)	(56)	(1,013,443)	(56)	(2,913,627)	(57)	(3,008,155)	(57)
5900	Net operating margin		768,922	44	791,084	44	2,209,600	43	2,285,684	43
	Operating expenses	6(8)(9)(27)(28)								
6100	Selling expenses		(135,068)	(8)	(185,248)	(10)	(454,759)	(9)	(574,388)	(11)
6200	General and administrative expenses		(178,178)	(10)	(193,504)	(11)	(535,883)	(10)	(574,469)	(11)
6300	Research and development expenses		(149,756)	(9)	(153,046)	(8)	(434,485)	(8)	(471,370)	(9)
6450	Expected credit impairment (loss) gain	12(3)	(2,350)	-	(15,670)	(1)	491	-	(22,226)	-
6000	Total operating expenses		(465,352)	(27)	(547,468)	(30)	(1,424,636)	(27)	(1,642,453)	(31)
6900	Operating profit		303,570	17	243,616	14	784,964	16	643,231	12
	Non-operating income and expenses									
7100	Interest income	6(23)	15,055	1	16,473	1	51,669	1	51,988	1
7010	Other income	6(24)	41,346	3	8,852	1	77,681	2	19,835	-
7020	Other gains and losses	6(25)	6,450	-	(12,192)	(1)	(39,239)	(1)	50,721	1
7050	Finance costs	6(26)	(10,810)	(1)	(11,556)	(1)	(35,474)	(1)	(32,995)	-
7060	Share of profit (loss) of associates and joint ventures accounted for using equity method	6(7)	(2,165)	-	532	-	(4,423)	-	(2,979)	-
7000	Total non-operating income and expenses		49,876	3	2,109	-	50,214	1	86,570	2
7900	**Profit before income tax**		353,446	20	245,725	14	835,178	17	729,801	14
7950	Income tax expense	6(29)	(60,222)	(3)	(53,489)	(3)	(100,275)	(2)	(87,548)	(2)
8200	**Profit for the period**		$ 293,224	17	$ 192,236	11	$ 734,903	15	$ 642,253	12
	Other comprehensive (loss) income									
	Components of other comprehensive (loss) income that will not be reclassified to profit or loss									
8316	Unrealised gains (losses) from investments in equity instruments measured at fair value through other comprehensive income	6(3)(21)	$ 3,860	-	($ 537)	-	$ 2,540	-	($ 906)	-
	Other comprehensive (loss) income that will be reclassified to profit or loss									
8361	Financial statements translation differences of foreign operations	6(21)	153,342	9	62,937	3	(192,001)	(4)	160,779	3
8300	**Total other comprehensive (loss) income for the period**		$ 157,202	9	$ 62,400	3	($ 189,461)	(4)	$ 159,873	3
8500	**Total comprehensive income for the period**		$ 450,426	26	$ 254,636	14	$ 545,442	11	$ 802,126	15
	Profit attributable to:									
8610	Owners of the parent		$ 274,271	16	$ 163,250	9	$ 648,913	13	$ 561,618	11
8620	Non-controlling interest		18,953	1	28,986	2	85,990	2	80,635	1
			$ 293,224	17	$ 192,236	11	$ 734,903	15	$ 642,253	12
	Comprehensive income attributable to:									
8710	Owners of the parent		$ 434,327	25	$ 226,393	12	$ 457,697	9	$ 723,097	14
8720	Non-controlling interest		16,099	1	28,243	2	87,745	2	79,029	1
			$ 450,426	26	$ 254,636	14	$ 545,442	11	$ 802,126	15
	Basic earnings per share (In dollars)	6(30)								
9750	Basic earnings per share		$	2.50	$	1.47	$	5.89	$	5.00
9850	Diluted earnings per share		$	2.50	$	1.47	$	5.86	$	4.97

The accompanying notes are an integral part of these consolidated financial statements.

TCI CO., LTD. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024
(Expressed in thousands of New Taiwan dollars)

		Equity attributable to owners of the parent										
				Retained earnings			Other equity interest					
	Notes	Share capital - common stock	Capital surplus, additional paid-in capital	Legal reserve	Special reserve	Unappropriated retained earnings	Financial statements translation differences of foreign operations	Unrealised gains (losses) from financial assets measured at fair value through other comprehensive income	Treasury shares	Total	Non-controlling interest	Total equity
For the nine months ended September 30, 2024												
Balance at January 1, 2024		$ 1,182,608	$ 2,900,420	$ 970,582	$ 194,104	$ 3,491,839	($ 280,381)	($ 3,152)	($ 232,963)	$8,223,057	$ 1,654,885	$ 9,877,942
Profit for the period		-	-	-	-	561,618	-	-	-	561,618	80,635	642,253
Other comprehensive income (loss) for the period	6(21)	-	-	-	-	-	162,385	(906)	-	161,479	(1,606)	159,873
Total comprehensive income (loss)		-	-	-	-	561,618	162,385	(906)	-	723,097	79,029	802,126
Legal reserve		-	-	89,626	-	(89,626)	-	-	-	-	-	-
Special reserve		-	-	-	104,790	(104,790)	-	-	-	-	-	-
Cash dividends		-	-	-	-	(824,102)	-	-	-	(824,102)	-	(824,102)
Share-based payments		-	1,076	-	-	-	-	-	-	1,076	-	1,076
Changes in equity of associates and joint ventures		-	(54,573)	-	-	-	-	-	-	(54,573)	-	(54,573)
Transactions with non-controlling interests		-	55,879	-	-	-	-	-	-	55,879	(55,879)	-
Acquisition of parent company's share by subsidiaries		-	-	-	-	-	-	-	(261,470)	(261,470)	(361,968)	(623,438)
Adjustment to non-controlling interests		-	-	-	-	-	-	-	-	-	(28,887)	(28,887)
Balance at September 30, 2024		$ 1,182,608	$ 2,902,802	$ 1,060,208	$ 298,894	$ 3,034,939	($ 117,996)	($ 4,058)	($ 494,433)	$7,862,964	$ 1,287,180	$ 9,150,144
For the nine months ended September 30, 2025												
Balance at January 1, 2025		$ 1,182,608	$ 2,893,400	$ 1,060,208	$ 298,894	$ 3,324,916	($ 151,239)	($ 2,741)	($ 509,948)	$8,096,098	$ 1,392,078	$ 9,488,176
Profit for the period		-	-	-	-	648,913	-	-	-	648,913	85,990	734,903
Other comprehensive income (loss) for the period	6(21)	-	-	-	-	-	(193,756)	2,540	-	(191,216)	1,755	(189,461)
Total comprehensive income (loss)		-	-	-	-	648,913	(193,756)	2,540	-	457,697	87,745	545,442
Appropriations of 2024 earnings	6(20)											
Legal reserve		-	-	85,159	-	(85,159)	-	-	-	-	-	-
Special reserve		-	-	-	(68,951)	68,951	-	-	-	-	-	-
Cash dividends		-	-	-	-	(835,875)	-	-	-	(835,875)	-	(835,875)
Cash dividends from capital surplus		-	(341,414)	-	-	-	-	-	-	(341,414)	-	(341,414)
Share-based payments		-	309	-	-	-	-	-	-	309	-	309
Changes in equity of associates and joint ventures		-	35,027	-	-	-	-	-	(13,475)	21,552	13,475	35,027
Transactions with non-controlling interests	6(31)	-	(78,929)	-	-	-	-	-	-	(78,929)	(38,834)	(117,763)
Treasury stock cancellation		(5,320)	(4,926)	-	-	(108,541)	-	-	118,787	-	-	-
Acquisition of parent company's share by subsidiaries		-	-	-	-	-	-	-	(29,558)	(29,558)	(40,434)	(69,992)
Adjustment to non-controlling interests		-	-	-	-	-	-	-	-	-	(72,742)	(72,742)
Disposal of financial assets measured at fair value through other comprehensive income	6(3)	-	-	-	-	2,067	-	(2,067)	-	-	-	-
Balance at September 30, 2025		$ 1,177,288	$ 2,503,467	$ 1,145,367	$ 229,943	$ 3,015,272	($ 344,995)	($ 2,268)	($ 434,194)	$7,289,880	$ 1,341,288	$ 8,631,168

The accompanying notes are an integral part of these consolidated financial statements.

TCI CO., LTD. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024
(Expressed in thousands of New Taiwan dollars)

	Notes	Nine months ended September 30 2025	2024
CASH FLOWS FROM OPERATING ACTIVITIES			
Profit before tax		$ 835,178	$ 729,801
Adjustments			
Adjustments to reconcile profit (loss)			
Depreciation	6(8)(9)(27)	395,517	416,415
Amortization	6(10)(27)	33,849	36,638
Expected credit impairment (gain) loss	12(3)	(491)	22,226
Net loss on financial assets at fair value through profit or loss	6(2)(13)(25)	3,094	1,252
(Gain) loss on disposal of property, plant and equipment	6(25)	(2,244)	506
Gain on disposal of investments	6(25)	1,725	468
Interest income	6(23)	(51,669)	(51,988)
Dividend income	6(24)	(4,142)	(3,164)
Interest expense	6(26)	35,474	32,995
Compensation cost arising from employee stock options	6(17)(28)	2,004	6,268
Share of profit of associates and joint ventures accounted for under the equity method	6(7)	4,423	2,979
Changes in operating assets and liabilities			
Changes in operating assets			
Notes receivable		56,512	8,647
Accounts receivable		(164,563)	29,944
Accounts receivable - related parties		42,076	(2,607)
Other receivables		(5,532)	(11,996)
Other receivables - related parties		60	(22)
Inventories		98,723	(17,894)
Prepayments		(51,025)	59,725
Other current assets		(4,384)	10,835
Changes in operating liabilities			
Contract liabilities - current		(147,284)	86,784
Notes payable		2,379	2,188
Accounts payable		(28,959)	(75,504)
Accounts payable - related parties		-	(2,751)
Other payables		67,806	35,380
Other payables - related parties		287	-
Other current liabilities		(30,144)	39,532
Other non-current liabilities		(561)	-
Cash inflow generated from operations		1,088,109	1,356,657
Interest received		70,557	51,988
Interest paid		(31,405)	(28,478)
Dividends received		4,142	3,164
Income tax paid		(239,238)	(425,430)
Net cash flows from operating activities		892,165	957,901

(Continued)

TCI CO., LTD. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024
(Expressed in thousands of New Taiwan dollars)

	Notes	Nine months ended September 30 2025	2024
CASH FLOWS FROM INVESTING ACTIVITIES			
Proceeds from disposal of non-current financial assets at fair value through other comprehensive income		$ 6,540	$ -
Acquisition of property, plant and equipment	6(32)	(150,063)	(61,149)
Proceeds from disposal of property, plant and equipment		25,018	743
Decrease in refundable deposits		14,987	2,137
Acquisition of intangible assets	6(10)	(1,656)	(425)
Decrease (increase) in other non-current assets		7,198	(113,917)
Acquisition of financial assets at fair value through profit or loss		(7,935)	-
Proceeds from disposal of financial assets at fair value through profit or loss		25,689	35,017
Decrease (increase) in financial assets at amortized cost	6(4)	601,846	(458,930)
Increase in investment accounted for using equity method	6(7)	(17,137)	(16,687)
Proceeds from disposal of investments accounted for using the equity method	6(7)	1,020	-
Net cash flows from (used in) investing activities		505,507	(613,211)
CASH FLOWS FROM FINANCING ACTIVITIES			
Proceeds from short-term borrowings		5,708,800	4,872,288
Repayments of short-term borrowings		(4,604,160)	(4,733,728)
Proceeds from long-term borrowings		-	500,000
Redemption of long-term borrowings		(79,951)	(258,230)
Lease liabilities paid		(57,007)	(56,958)
Increase (decrease) in guarantee deposits		6,968	(5,948)
Cash dividends paid		(1,177,289)	(824,102)
Cash dividends paid to non-controlling interest		(47,129)	(31,967)
Acquisition of the Company's share by subsidiaries recognized as treasury shares	6(18)	(69,992)	(623,438)
Consideration for transactions with non-controlling interests		(117,763)	-
Net cash flows used in financing activities		(437,523)	(1,162,083)
Effects due to changes in exchange rate		(223,218)	104,114
Net increase (decrease) in cash and cash equivalents		736,931	(713,279)
Cash and cash equivalents at beginning of period	6(1)	4,767,212	5,363,426
Cash and cash equivalents at end of period	6(1)	$ 5,504,143	$ 4,650,147

The accompanying notes are an integral part of these consolidated financial statements.

TCI CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024
(Expressed in thousands of New Taiwan dollars, except as otherwise indicated)

1. HISTORY AND ORGANIZATION

TCI CO., LTD. (the "Company") was incorporated as a company limited by shares under the provisions of the Company Act of the Republic of China (R.O.C.). The Company and its subsidiaries (collectively referred herein as the "Group") are primarily engaged in manufacturing, wholesale and retail of health foods and cosmetics.

2. THE DATE OF AUTHORIZATION FOR ISSUANCE OF THE CONSOLIDATED FINANCIAL STATEMENTS AND PROCEDURES FOR AUTHORIZATION

These consolidated financial statements were reported to the Board of Directors on November 11, 2025.

3. APPLICATION OF NEW STANDARDS, AMENDMENTS AND INTERPRETATIONS

(1) Effect of the adoption of new issuances of or amendments to International Financial Reporting Standards ("IFRS®") Accounting Standards that came into effect as endorsed by the Financial Supervisory Commission ("FSC")

New standards, interpretations and amendments endorsed by the FSC and became effective from 2025 are as follows:

New Standards, Interpretations and Amendments	Effective date by International Accounting Standards Board
Specific provisions of Amendments to IFRS 9 and IFRS 7, 'Amendments to the classification and measurement of financial instruments'	January 1, 2026
Amendments to IAS 21, 'Lack of exchangeability'	January 1, 2025

The above standards and interpretations have no significant impact to the Group's financial condition and financial performance based on the Group's assessment.

(2) Effect of new issuances of or amendments to IFRS Accounting Standards as endorsed by the FSC but not yet adopted by the Group

New standards, interpretations and amendments endorsed by the FSC effective from 2026 are as follows:

New Standards, Interpretations and Amendments	Effective date by International Accounting Standards Board
Specific provisions of Amendments to IFRS 9 and IFRS 7, ‘Amendments to the classification and measurement of financial instruments’	January 1, 2026
Amendments to IFRS 9 and IFRS 7, ‘Contracts referencing nature-dependent electricity’	January 1, 2026
IFRS 17, ‘Insurance contracts’	January 1, 2023
Amendments to IFRS 17, ‘Insurance contracts’	January 1, 2023
Amendment to IFRS 17, ‘Initial application of IFRS 17 and IFRS 9 – comparative information’	January 1, 2023
Annual Improvements to IFRS Accounting Standards—Volume 11	January 1, 2026

The above standards and interpretations have no significant impact to the Group’s financial condition and financial performance based on the Group’s assessment.

(3) IFRS Accounting Standards issued by IASB but not yet endorsed by the FSC

New standards, interpretations and amendments issued by IASB but not yet included in the IFRS Accounting Standards as endorsed by the FSC are as follows:

New Standards, Interpretations and Amendments	Effective date by International Accounting Standards Board
Amendments to IFRS 10 and IAS 28, ‘Sale or contribution of assets between an investor and its associate or joint venture’	To be determined by International Accounting Standards Board
IFRS 18, ‘Presentation and disclosure in financial statements’	January 1, 2027 (Note)
IFRS 19, ‘Subsidiaries without public accountability: disclosures’	January 1, 2027

Note：The FSC has announced in a press release on September 25, 2025 that public companies will apply IFRS 18 starting from the fiscal year 2028. Additionally, entities can choose to adopt IFRS 18 earlier based on their requirements after the FSC endorses IFRS 18.

Except for the following, the above standards and interpretations have no significant impact to the Group’s financial condition and financial performance based on the Group’s assessment.

IFRS 18, ‘Presentation and disclosure in financial statements’

IFRS 18, ‘Presentation and disclosure in financial statements’ replaces IAS 1. The standard introduces a defined structure of the statement of profit or loss, disclosure requirements related to management-defined performance measures, and enhanced principles on aggregation and disaggregation which apply to the primary financial statements and notes.

4. SUMMARY OF MATERIAL ACCOUNTING POLICIES

The principal accounting policies applied in the preparation of these consolidated financial statements are set out below. These policies have been consistently applied to all the periods presented, unless otherwise stated.

(1) Compliance statement

The consolidated financial statements of the Group have been prepared in accordance with the "Regulations Governing the Preparation of Financial Reports by Securities Issuers" and the International Accounting Standard 34, 'Interim financial reporting' that came into effect as endorsed by the FSC.

(2) Basis of preparation

A. Except for the following items, the consolidated financial statements have been prepared under the historical cost convention:

(a) Financial assets and financial liabilities (including derivative instruments) at fair value through profit or loss.

(b) Financial assets at fair value through other comprehensive income.

(c) Defined benefit liabilities recognized based on the net amount of pension fund assets less present value of defined benefit obligation.

B. The preparation of financial statements in conformity with "IFRSs" requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Group's accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the consolidated financial statements are disclosed in Note 5.

(3) Basis of consolidation

A. Basis for preparation of consolidated financial statements:

(a) All subsidiaries are included in the Group's consolidated financial statements. Subsidiaries are all entities (including structured entities) controlled by the Group. The Group controls an entity when the Group is exposed, or has rights, to variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. Consolidation of subsidiaries begins from the date the Group obtains control of the subsidiaries and ceases when the Group loses control of the subsidiaries.

(b) Inter-company transactions, balances and unrealized gains or losses on transactions between companies within the Group are eliminated. Accounting policies of subsidiaries have been adjusted where necessary to ensure consistency with the policies adopted by the Group.

(c) Profit or loss and each component of other comprehensive income are attributed to the owners of the parent and to the non-controlling interests. Total comprehensive income is attributed to the owners of the parent and to the non-controlling interests even if this results in the non-controlling interests having a deficit balance.

(d) Changes in a parent's ownership interest in a subsidiary that do not result in the parent losing control of the subsidiary (transactions with non-controlling interests) are accounted for as equity transactions, i.e. transactions with owners in their capacity as owners. Any difference between the amount by which the non-controlling interests are adjusted and the fair value of the consideration paid or received is recognized directly in equity.

(e) When the Group loses control of a subsidiary, the Group remeasures any investment retained in the former subsidiary at its fair value. That fair value is regarded as the fair value on initial recognition of a financial asset or the cost on initial recognition of the associate or joint venture. Any difference between fair value and carrying amount is recognized in profit or loss. All amounts previously recognized in other comprehensive income in relation to the subsidiary are reclassified to profit or loss on the same basis as would be required if the related assets or liabilities were disposed of. That is, when the Group loses control of a subsidiary, all gains or losses previously recognized in other comprehensive income in relation to the subsidiary should be reclassified from equity to profit or loss, if such gains or losses would be reclassified to profit or loss when the related assets or liabilities are disposed of.

B. Subsidiaries included in the consolidated financial statements:

			Ownership (%)			
Name of investor	Name of subsidiary	Main business activities	September 30, 2025	December 31, 2024	September 30, 2024	Description
TCI CO., LTD.	TCI FIRSTEK CORP.	Wholesale and retail of health foods and cosmetics	100	100	100	
TCI CO., LTD.	GENE & NEXT INC.	Research and development of biotechnology and genetics	42.23	42.23	41.94	
TCI CO., LTD.	TCI Biotech Co., Ltd	Producing health foods	36.73	36.73	36.73	
TCI CO., LTD.	TCI HK LIMITED	Trading health foods and cosmetics	100	100	100	
TCI CO., LTD.	BIOCOSME CO., LTD.	Trading health foods and cosmetics	100	100	100	
TCI CO., LTD.	PETFOOD BIOTECHNOLOGY CO., LTD.	Trading health foods for pets	-	-	56	Note 3

Name of investor	Name of subsidiary	Main business activities	Ownership (%) September 30, 2025	Ownership (%) December 31, 2024	Ownership (%) September 30, 2024	Description
TCI FIRSTEK CORP.	TCI International Trading Co., Ltd	Wholesale of health foods, cosmetics and chemical productions; cosmetics manufacturing	100	100	100	
GENE & NEXT INC.	GLUX HK LIMITED	Trading health foods and cosmetics	100	100	100	
TCI International Trading Co., Ltd	SHANGHAI BIOSCIENCE CO., LTD.	Wholesale of health foods, cosmetics and chemical productions; cosmetics manufacturing	100	100	100	
TCI International Trading Co., Ltd	SHANGHAI BIOCOSME CO., LTD.	Producing cosmetics	100	100	100	
SHANGHAI BIOSCIENCE CO., LTD.	TCI Biotech Co., Ltd	Producing health foods	63.27	63.27	63.27	
GENE & NEXT INC.	TCI LIVING CO., LTD.	Trading health foods and cosmetics	79.31	79.31	79.31	
TCI LIVING CO., LTD.	TCI LIVING (HK) LIMITED	Trading health foods and cosmetics	100	100	100	
TCI CO., LTD.	TCI JAPAN CO., LTD.	Trading health foods and cosmetics	100	100	100	
TCI CO., LTD.	PT TCI BIOTEK INDO	Trading health foods and cosmetics	100	100	100	Note 1
SHANGHAI BIOSCIENCE CO., LTD.	SHANGHAI BIOTECH GENE TECHNOLOGY CO., LTD.	Research and development of biotechnology and genetics	-	-	-	Note 2
TCI CO., LTD.	TCI BIOTECH NETHERLANDS B.V.	Trading health foods and cosmetics	100	100	100	
TCI LIVING CO., LTD.	TCI LIVING SHANGHAI CO., LTD.	Trading health foods and cosmetics	100	100	100	

Name of investor	Name of subsidiary	Main business activities	Ownership (%) September 30, 2025	December 31, 2024	September 30, 2024	Description
TCI CO., LTD.	QUANTUM BIOLOGY INC.	Research and development of biotechnology	100	100	100	
TCI CO., LTD.	AYURGA INDIA PRIVATE LIMITED	Trading health foods and cosmetics	100	-	-	Note 4
TCI CO., LTD.	TCI BIOTECH LLC	Trading health foods and cosmetics	3.85	3.85	3.85	
TCI BIOTECH LLC	TCI BIOTECH USA LLC	Trading health foods and cosmetics	100	100	100	
TCI BIOTECH NETHERLANDS B.V.	TCI BIOTECH LLC	Trading health foods and cosmetics	96.15	96.15	96.15	
TCI CO., LTD.	MAXIGEN BIOTECH INC.	Research and development, producing and sales of biotechnology and cosmetics	28.26	25.42	25.01	
MAXIGEN BIOTECH INC.	Maxigen Biotech Shanghai Co., Ltd.	Selling medical machinery and trading cosmetics	100	100	100	

Note 1: There was capital injection of $17,635 on June 12, 2024.

Note 2: The company was dissolved and liquidated on April 23, 2024.

Note 3: The company underwent dissolution and liquidation in 2024. However, as of September 30, 2025, the liquidation process had not yet been completed.

Note 4: There was capital injection of $9,209 on June 1, 2025.

C. Subsidiaries not included in the consolidated financial statements: None.

D. Adjustments for subsidiaries with different balance sheet dates: None.

E. Significant restrictions:

Cash and short-term deposits of $2,369,350 deposited in mainland China are under local foreign exchange control which restricts the capital to be remitted outside the borders (except for normal dividend distribution).

F. Subsidiaries that have non-controlling interests that are material to the Group:

Information on subsidiaries that have non-controlling interests that are material to the Group is as follows:

Name of subsidiary	Principal place of business	Non-controlling interests			
		September 30, 2025		September 30, 2024	
		Amount	Ownership (%)	Amount	Ownership (%)
GENE & NEXT INC.	Taiwan	$ 163,283	57.77%	$ 242,089	58.06%
MAXIGEN BIOTECH INC.	Taiwan	1,178,005	71.74%	1,037,063	74.99%

Summarized financial information of the subsidiaries:

Balance sheets

	GENE & NEXT INC.		
	September 30, 2025	December 31, 2024	September 30, 2024
Current assets	$ 964,562	$ 994,284	$ 1,052,186
Non-current assets	97,050	104,819	90,972
Current liabilities	(96,242)	(101,291)	(116,902)
Non-current liabilities	(4,904)	-	-
Total net assets	$ 960,466	$ 997,812	$ 1,026,256

	MAXIGEN BIOTECH INC.		
	September 30, 2025	December 31, 2024	September 30, 2024
Current assets	$ 950,139	$ 830,334	$ 744,225
Non-current assets	757,419	752,155	788,722
Current liabilities	(226,545)	(205,869)	(196,624)
Non-current liabilities	(7,460)	(1,493)	(1,731)
Total net assets	$ 1,473,553	$ 1,375,127	$ 1,334,592

Statements of comprehensive income

	GENE & NEXT INC.	
	Three months ended September 30,	
	2025	2024
Revenue	$ 71,468	$ 80,014
Profit before income tax	48,793	24,355
Income tax expense	(265)	(314)
Profit attributable to non-controlling interest	807	377
Profit attributable to owners of the parent	47,721	23,664
Other comprehensive loss, net of tax	(16,446)	(62,428)
Total comprehensive income (loss) for the period	$ 32,082	($ 38,387)
Comprehensive income attributable to non-controlling interest	$ 526	$ 10,533
Dividends paid to non-controlling interest	$ 28,972	$ 18,289

	GENE & NEXT INC.	
	Nine months ended September 30,	
	2025	2024
Revenue	$ 213,175	$ 244,526
Profit before income tax	53,590	54,684
Income tax expense	(4,433)	(7,567)
Profit attributable to non-controlling interest	(1,658)	(152)
Profit attributable to owners of the parent	50,815	47,269
Other comprehensive loss, net of tax	(28,192)	(4,796)
Total comprehensive income for the period	$ 20,965	$ 42,321
Comprehensive income attributable to non-controlling interest	$ 5,564	$ 10,225
Dividends paid to non-controlling interest	$ 28,972	$ 18,289

	MAXIGEN BIOTECH INC.	
	Three months ended September 30,	
	2025	2024
Revenue	$ 200,856	$ 173,941
Profit before income tax	89,485	69,868
Income tax expense	(13,950)	(20,346)
Profit for the period	75,535	49,522
Other comprehensive loss, net of tax	(15,359)	(50,146)
Total comprehensive income (loss) for the period	$ 60,176	($ 624)
Comprehensive income attributable to non-controlling interest	$ 15,573	$ 19,206
Dividends paid to non-controlling interest	$ 18,157	$ 13,678

	MAXIGEN BIOTECH INC.	
	Nine months ended September 30,	
	2025	2024
Revenue	$ 586,858	$ 475,016
Profit before income tax	202,443	156,471
Income tax expense	(20,872)	(18,800)
Profit for the period	181,571	137,671
Other comprehensive loss, net of tax	(10,419)	(88,100)
Total comprehensive income for the period	$ 171,152	$ 49,571
Comprehensive income attributable to non-controlling interest	$ 82,181	$ 72,942
Dividends paid to non-controlling interest	$ 18,157	$ 13,678

Statements of cash flows

	GENE & NEXT INC.	
	Nine months ended September 30,	
	2025	2024
Net cash provided by operating activities	$ 138,540	$ 66,006
Net cash provided by (used in) investing activities	109,602	(593,390)
Net cash used in financing activities	(58,101)	(31,487)
Effect of exchange rate changes on cash and cash equivalents	(689)	193
Increase (decrease) in cash and cash equivalents	189,352	(558,678)
Cash and cash equivalents at beginning of period	98,426	696,046
Cash and cash equivalents at end of period	$ 287,778	$ 137,368

	MAXIGEN BIOTECH INC.	
	Nine months ended September 30,	
	2025	2024
Net cash provided by operating activities	$ 194,100	$ 215,351
Net cash used in investing activities	(37,644)	(20,214)
Net cash provided by financing activities	(67,892)	(80,412)
Effect of exchange rate changes on cash and cash equivalents	3,501	(2,046)
Increase in cash and cash equivalents	92,065	112,679
Cash and cash equivalents at beginning of period	639,054	431,082
Cash and cash equivalents at end of period	$ 731,119	$ 543,761

(4) Foreign currency translation

Items included in the financial statements of each of the Group's entities are measured using the

currency of the primary economic environment in which the entity operates (the "functional currency"). The consolidated financial statements are presented in New Taiwan dollars (NTD), which is the Company's functional and the Group's presentation currency.

A. Foreign currency transactions and balances

(a) Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions or valuation where items are remeasured. Foreign exchange gains and losses resulting from the settlement of such transactions are recognized in profit or loss in the period in which they arise.

(b) Monetary assets and liabilities denominated in foreign currencies at the period end are retranslated at the exchange rates prevailing at the balance sheet date. Exchange differences arising upon re-translation at the balance sheet date are recognized in profit or loss.

(c) Non-monetary assets and liabilities denominated in foreign currencies held at fair value through profit or loss are re-translated at the exchange rates prevailing at the balance sheet date; their translation differences are recognized in profit or loss. Non-monetary assets and liabilities denominated in foreign currencies held at fair value through other comprehensive income are re-translated at the exchange rates prevailing at the balance sheet date; their translation differences are recognized in other comprehensive income. However, non-monetary assets and liabilities denominated in foreign currencies that are not measured at fair value are translated using the historical exchange rates at the dates of the initial transactions.

(d) All foreign exchange gains and losses are presented in the statement of comprehensive income within 'other gains and losses'.

B. Translation of foreign operations

(a) The operating results and financial position of all the group entities arrangements that have a functional currency different from the presentation currency are translated into the presentation currency as follows:

i. Assets and liabilities for each balance sheet presented are translated at the closing exchange rate at the date of that balance sheet;

ii. Income and expenses for each statement of comprehensive income are translated at average exchange rates of that period; and

iii. All resulting exchange differences are recognized in other comprehensive income.

(b) When the foreign operation partially disposed of or sold is a subsidiary, cumulative exchange differences that were recorded in other comprehensive income are proportionately transferred to the non-controlling interest in this foreign operation. In addition, even when the Group retains partial interest in the former foreign subsidiary after losing control of the former foreign subsidiary, such transactions should be accounted for as disposal of all interest in the foreign operation.

(5) Classification of current and non-current items

A. Assets that meet one of the following criteria are classified as current assets; otherwise they are classified as non-current assets:

(a) Assets that are expected to be realized, or are intended to be sold or consumed in the normal operating cycle;
(b) Assets that are held primarily for the purpose of trading;
(c) Assets that are expected to be realized within twelve months after the reporting period;
(d) Cash and cash equivalents, excluding restricted cash and cash equivalents and those that are to be exchanged or used to settle liabilities for at least twelve months after the reporting period.

B. Liabilities that meet one of the following criteria are classified as current liabilities; otherwise they are classified as non-current liabilities:
(a) Liabilities that are expected to be settle in the normal operating cycle;
(b) Liabilities that are held primarily for the purpose of trading;
(c) Liabilities that are due to be settle within twelve months after the reporting period;
(d) It does not have the right at the end of the reporting period to defer settlement of the liability at least twelve months after the reporting period.

(6) Cash equivalents

Cash equivalents refer to short-term, highly liquid investments that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value. Time deposits that meet the definition above and are held for the purpose of meeting short-term cash commitments in operations are classified as cash equivalents.

(7) Financial assets at fair value through profit or loss

A. Financial assets at fair value through profit or loss are financial assets that are not measured at amortized cost or fair value through other comprehensive income.

B. On a regular way purchase or sale basis, financial assets at fair value through profit or loss are recognized and derecognized using trade date accounting.

C. At initial recognition, the Group measures the financial assets at fair value and recognizes the transaction costs in profit or loss. The Group subsequently measures the financial assets at fair value, and recognizes the gain or loss in profit or loss.

D. The Group recognizes the dividend income when the right to receive payment is established, future economic benefits associated with the dividend will flow to the Group and the amount of the dividend can be measured reliably.

(8) Financial assets at fair value through other comprehensive income

A. Financial assets at fair value through other comprehensive income comprise equity securities which are not held for trading, and for which the Group has made an irrevocable election at initial recognition to recognize changes in fair value in other comprehensive income and debt instruments.

B. On a regular way purchase or sale basis, financial assets at fair value through other comprehensive income are recognized and derecognized using trade date accounting.

C. At initial recognition, the Group measures the financial assets at fair value plus transaction costs. The Group subsequently measures the financial assets at fair value:

The changes in fair value of equity investments that were recognized in other comprehensive income are reclassified to retained earnings and are not reclassified to profit or loss following the derecognition of the investment. Dividends are recognized as revenue when the right to receive payment is established, future economic benefits associated with the dividend will flow to the Group and the amount of the dividend can be measured reliably.

(9) Financial assets at amortized cost

A. Financial assets at amortized cost are those that meet all of the following criteria:
   (a) The objective of the Group's business model is achieved by collecting contractual cash flows.
   (b) The assets' contractual cash flows represent solely payments of principal and interest.

B. On a regular way purchase or sale basis, financial assets at amortized cost are recognized and derecognized using trade date accounting.

C. The Group's time deposits which do not fall under cash equivalents are those with a short maturity period and are measured at initial investment amount as the effect of discounting is immaterial.

(10) Accounts and notes receivable

A. Accounts and notes receivable entitle the Group a legal right to receive consideration in exchange for transferred goods or rendered services.

B. The short-term accounts and notes receivable without bearing interest are subsequently measured at initial invoice amount as the effect of discounting is immaterial.

(11) Impairment of financial assets

For debt instruments measured at fair value through other comprehensive income and financial assets at amortized cost including accounts receivable that have a significant financiang component, at each reporting date, the Group recognizes the impairment provision for 12 months expected credit losses if there has not been a significant increase in credit risk since initial recognition or recognizes the impairment provision for the lifetime expected credit losses (ECLs) if such credit risk has increased since initial recognition after taking into consideration all reasonable and verifiable information that includes forecasts. On the other hand, for accounts receivable or contract assets that do not contain a significant financing component, the Group recognizes the impairment provision for lifetime ECLs.

(12) Derecognition of financial assets

The Group derecognizes a financial asset when one of the following conditions is met:

A. The contractual rights to receive the cash flows from the financial asset expire.

B. The contractual rights to receive cash flows of the financial asset have been transferred and the Group has transferred substantially all risks and rewards of ownership of the financial asset.

C. The contractual rights to receive cash flows of the financial asset have been transferred; however, the Group has not retained control of the financial asset.

(13) Leasing arrangements (lessor)－lease receivables/ operating leases

Lease income from an operating lease (net of any incentives given to the lessee) is recognized in profit or loss on a straight-line basis over the lease term.

(14) Inventories

Inventories are stated at the lower of cost and net realizable value. Cost is determined using the weighted-average method. The cost of finished goods and work in progress comprises raw materials, direct labor, other direct costs and related production overheads (allocated based on normal operating capacity). It excludes borrowing costs. The item by item approach is used in applying the lower of cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less the estimated cost of completion and the estimated costs necessary to make the sale.

(15) Investments accounted for using equity method / associates

A. Associates are all entities over which the Group has significant influence but not control. In general, it is presumed that the investor has significant influence, if an investor holds, directly or indirectly 20 percent or more of the voting power of the investee. Investments in associates are accounted for using the equity method and are initially recognized at cost.

B. The Group's share of its associates' post-acquisition profits or losses is recognized in profit or loss, and its share of post-acquisition movements in other comprehensive income is recognized in other comprehensive income. When the Group's share of losses in an associate equals or exceeds its interest in the associate, including any other unsecured receivables, the Group does not recognize further losses, unless it has incurred legal or constructive obligations or made payments on behalf of the associate.

C. When changes in an associate's equity do not arise from profit or loss or other comprehensive income of the associate and such changes do not affect the Group's ownership percentage of the associate, the Group recognizes the Group's share of change in equity of the associate in 'capital surplus' in proportion to its ownership.

D. Unrealized gains on transactions between the Group and its associates are eliminated to the extent of the Group's interest in the associates. Unrealized losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred. Accounting policies of associates have been adjusted where necessary to ensure consistency with the policies adopted by the Group.

E. In the case that an associate issues new shares and the Group does not subscribe or acquire new shares proportionately, which results in a change in the Group's ownership percentage of the associate but maintains significant influence on the associate, then 'capital surplus' and 'investments accounted for under the equity method' shall be adjusted for the increase or decrease of its share of equity interest. If the above condition causes a decrease in the Group's ownership percentage of the associate, in addition to the above adjustment, the amounts previously recognized in other comprehensive income in relation to the associate are reclassified to profit or loss proportionately on the same basis as would be required if the relevant assets or liabilities were disposed of.

F. When the Group disposes its investment in an associate and loses significant influence over this

associate, the amounts previously recognized in other comprehensive income in relation to the associate, are reclassified to profit or loss, on the same basis as would be required if the relevant assets or liabilities were disposed of. If it retains significant influence over this associate, the amounts previously recognized in other comprehensive income in relation to the associate are reclassified to profit or loss proportionately in accordance with the aforementioned approach.

G. At the balance sheet date, the Group performs an impairment test for an investment in an associate when there is an indication that the investment may be impaired. The entire carrying amount of the investment (including goodwill) is tested for impairment as a single asset, by comparing its recoverable amount (higher of value in use and fair value less costs of disposal) with its carrying amount. Any impairment loss recognized forms part of the carrying amount of the investment. Any reversal of impairment loss is recognized to the extent that the recoverable amount of the investment subsequently increases.

(16) Property, plant and equipment

A. Property, plant and equipment are initially recorded at cost. Borrowing costs incurred during the construction period are capitalized.

B. Subsequent costs are included in the asset's carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Group and the cost of the item can be measured reliably. The carrying amount of the replaced part is derecognized. All other repairs and maintenance are charged to profit or loss during the financial period in which they are incurred.

C. Land is not depreciated. Other property, plant and equipment apply cost model and are depreciated using the straight-line method to allocate their cost over their estimated useful lives. Each part of an item of property, plant, and equipment with a cost that is significant in relation to the total cost of the item must be depreciated separately.

D. The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted if appropriate, at each financial year-end. If expectations for the assets' residual values and useful lives differ from previous estimates or the patterns of consumption of the assets' future economic benefits embodied in the assets have changed significantly, any change is accounted for as a change in estimate under IAS 8, 'Accounting Policies, Changes in Accounting Estimates and Errors', from the date of the change. The estimated useful lives of property, plant and equipment are as follows:

Buildings and structures	3 ~ 50 years
Machinery and equipment	2 ~ 10 years
Office equipment	1 ~ 16 years
Others	1 ~ 16 years

(17) Leasing arrangements (lessee)-right-of-use assets/ lease liabilities

A. Leases are recognized as a right-of-use asset and a corresponding lease liability at the date at which the leased asset is available for use by the Group. For short-term leases or leases of low-

value assets, lease payments are recognized as an expense on a straight-line basis over the lease term.

B. Lease liabilities include the net present value of the remaining lease payments at the commencement date, discounted using the incremental borrowing interest rate. Lease payments are comprised of the following:

(a) Fixed payments, less any lease incentives receivable;

(b) Variable lease payments that depend on an index or a rate.

The Group subsequently measures the lease liability at amortized cost using the interest method and recognizes interest expense over the lease term. The lease liability is remeasured and the amount of remeasurement is recognized as an adjustment to the right-of-use asset when there are changes in the lease term or lease payments and such changes do not arise from contract modifications.

C. At the commencement date, the right-of-use asset is stated at cost comprising the following:

(a) The amount of the initial measurement of lease liability;

(b) Any lease payments made at or before the commencement date.

The right-of-use asset is measured subsequently using the cost model and is depreciated from the commencement date to the earlier of the end of the asset's useful life or the end of the lease term. When the lease liability is remeasured, the amount of remeasurement is recognized as an adjustment to the right-of-use asset.

D. For lease modifications that decrease the scope of the lease, the lessee shall decrease the carrying amount of the right-of-use asset to reflect the partial or full termination of the lease, and recognize the difference between remeasured lease liability in profit or loss. For all other lease modifications, the lessee shall remeasure the lease liability and adjust the right-of-use asset, correspondingly.

(18) Intangible assets

A. Trademarks and royalties

Separately acquired trademarks and royalties are stated at historical cost. Trademarks, licenses and other intangible assets acquired in a business combination are recognized at fair value at the acquisition date. Trademarks and royalties have a finite useful life and are amortized on a straight-line basis over their estimated useful lives of 3 to 10 years.

B. Computer software

Computer software is stated at cost and amortized on a straight-line basis over its estimated useful life of 1 to 10 years.

C. Goodwill

Goodwill arises in a business combination accounted for by applying the acquisition method.

D. Customer relationship

Customer relationship arises in a business combination accounted for by applying the acquisition method and amortized on a straight-line basis over their estimated useful life of 10 years.

(19) Impairment of non-financial assets

A. The Group assesses at each balance sheet date the recoverable amounts of those assets where there is an indication that they are impaired. An impairment loss is recognized for the amount by which the asset's carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset's fair value less costs to sell or value in use. When the circumstances or reasons for recognizing impairment loss for an asset in prior years no longer exist or diminish, the impairment loss is reversed. The increased carrying amount due to reversal should not be more than what the depreciated or amortized historical cost would have been if the impairment had not been recognized.

B. The recoverable amounts of goodwill, intangible assets with an indefinite useful life and intangible assets that have not yet been available for use are evaluated periodically. An impairment loss is recognized for the amount by which the asset's carrying amount exceeds its recoverable amount. Impairment loss of goodwill previously recognized in profit or loss shall not be reversed in the following years.

C. For the purpose of impairment testing, goodwill acquired in a business combination is allocated to each of the cash-generating units, or groups of cash-generating units, that is/are expected to benefit from the synergies of the business combination. Each unit or group of units to which the goodwill is allocated represents the lowest level within the entity at which the goodwill is monitored for internal management purposes. Goodwill is monitored at the operating segment level.

(20) Borrowings

Borrowings comprise long-term and short-term bank borrowings. Borrowings are recognized initially at fair value, net of transaction costs incurred. Borrowings are subsequently stated at amortized cost; any difference between the proceeds (net of transaction costs) and the redemption value is recognized in profit or loss over the period of the borrowings using the effective interest method.

(21) Notes and accounts payable

A. Notes and accounts payable are liabilities for purchases of raw materials, goods or services and notes payable are those resulting from operating and non-operating activities.

B. The short-term notes and accounts payable without bearing interest are subsequently measured at initial invoice amount as the effect of discounting is immaterial.

(22) Derecognition of financial liabilities

A financial liability is derecognized when the obligation under the liability specified in the contract is discharged or cancelled or expires.

(23) Offsetting financial instruments

Financial assets and liabilities are offset and reported in the net amount in the balance sheet when there is a legally enforceable right to offset the recognized amounts and there is an intention to settle on a net basis or realize the asset and settle the liability simultaneously.

(24) Employee benefits

A. Short-term employee benefits

Short-term employee benefits are measured at the undiscounted amount of the benefits expected to be paid in respect of service rendered by employees in a period and should be recognized as expense in that period when the employees render service.

B. Pensions

(a) Defined contribution plans

For defined contribution plans, the contributions are recognized as pension expense when they are due on an accrual basis. Prepaid contributions are recognized as an asset to the extent of a cash refund or a reduction in the future payments.

(b) Defined benefit plans

i. Net obligation under a defined benefit plan is defined as the present value of an amount of pension benefits that employees will receive on retirement for their services with the Group in current period or prior periods. The liability recognized in the balance sheet in respect of defined benefit pension plans is the present value of the defined benefit obligation at the balance sheet date less the fair value of plan assets. The net defined benefit obligation is calculated annually by independent actuaries using the projected unit credit method. The rate used to discount is determined by using interest rates of high-quality corporate bonds that are denominated in the currency in which the benefits will be paid, and that have terms to maturity approximating to the terms of the related pension liability; when there is no deep market in high-quality corporate bonds, the Group uses interest rates of government bonds (at the balance sheet date) instead.

ii. Remeasurements arising on defined benefit plans are recognized in other comprehensive income in the period in which they arise and are recorded as retained earnings.

iii. Pension cost for the interim period is calculated on a year-to-date basis by using the pension cost rate derived from the actuarial valuation at the end of the prior financial year, adjusted for significant market fluctuations since that time and for significant curtailments, settlements, or other significant one-off events. Also, the related information is disclosed accordingly.

C. Termination benefits

Termination benefits are employee benefits provided in exchange for the termination of employment as a result from either the Group's decision to terminate an employee's employment before the normal retirement date, or an employee's decision to accept an offer of redundancy benefits in exchange for the termination of employment. The Group recognizes expense as it can no longer withdraw an offer of termination benefits or it recognizes relating restructuring costs, whichever is earlier. Benefits that are expected to be due more than 12 months after balance sheet date shall be discounted to their present value.

D. Employees' compensation and directors' and supervisors' remuneration

Employees' compensation and directors' and supervisors' remuneration are recognized as

expense and liability, provided that such recognition is required under legal or constructive obligation and those amounts can be reliably estimated. Any difference between the resolved amounts and the subsequently actual distributed amounts is accounted for as changes in estimates.

(25) Employee share-based payment

A. For the equity-settled share-based payment arrangements, the employee services received are measured at the fair value of the equity instruments granted at the grant date, and are recognized as compensation cost over the vesting period, with a corresponding adjustment to equity. The fair value of the equity instruments granted shall reflect the impact of market vesting conditions and vesting conditions. Compensation cost is subject to adjustment based on the service conditions that are expected to be satisfied and the estimates of the number of equity instruments that are expected to vest under the non-market vesting conditions at each balance sheet date. Ultimately, the amount of compensation cost recognized is based on the number of equity instruments that eventually vest.

B. Restricted stocks:

(a) Restricted stocks issued to employees are measured at the fair value of the equity instruments granted at the grant date, and are recognized as compensation cost over the vesting period.

(b) For restricted stocks where those stocks do not restrict distribution of dividends to employees but employees must return the dividends received if they resign during the vesting period, and the Group recognizes the fair value of the dividends received by the employees who are expected to resign during the vesting period as compensation cost at the date of dividends declared.

(c) For restricted stocks where employees have to pay to acquire those stocks, if the employees resign during the vesting period, they must return the stocks to the Group and the Group must refund their payments on the stocks, the Group recognizes the payments from the employees who are expected to resign during the vesting period as liabilities at the grant date, and recognizes the payments from the employees who are expected to be eventually vested with the stocks in 'capital surplus – others'.

(26) Income tax

A. The tax expense for the period comprises current and deferred tax. Tax is recognized in profit or loss, except to the extent that it relates to items recognized in other comprehensive income or items recognized directly in equity, in which cases the tax is recognized in other comprehensive income or equity.

B. The current income tax expense is calculated on the basis of the tax laws enacted or substantively enacted at the balance sheet date in the countries where the Company and its subsidiaries operate and generate taxable income. Management periodically evaluates positions taken in tax returns with respect to situations in accordance with applicable tax regulations. It establishes provisions

where appropriate based on the amounts expected to be paid to the tax authorities. An additional tax is levied on the unappropriated retained earnings and is recorded as income tax expense in the year the stockholders resolve to retain the earnings.

C. Deferred tax is recognized, using the balance sheet liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated balance sheet. However, the deferred tax is not accounted for if it arises from initial recognition of goodwill or of an asset or liability in a transaction other than a business combination that at the time of the transaction affects neither accounting nor taxable profit or loss and does not give rise to equal taxable and deductible temporary differences. Deferred tax is provided on temporary differences arising on investments in subsidiaries, except where the timing of the reversal of the temporary difference is controlled by the Group and it is probable that the temporary difference will not reverse in the foreseeable future. Deferred tax is determined using tax rates (and laws) that have been enacted or substantially enacted by the balance sheet date and are expected to apply when the related deferred tax asset is realized or the deferred tax liability is settled.

D. Deferred tax assets are recognized only to the extent that it is probable that future taxable profit will be available against which the temporary differences can be utilized. At each balance sheet date, unrecognized and recognized deferred tax assets are reassessed.

E. Current income tax assets and liabilities are offset and the net amount reported in the balance sheet when there is a legally enforceable right to offset the recognized amounts and there is an intention to settle on a net basis or realize the asset and settle the liability simultaneously. Deferred tax assets and liabilities are offset on the balance sheet when the entity has the legally enforceable right to offset current tax assets against current tax liabilities and they are levied by the same taxation authority on either the same entity or different entities that intend to settle on a net basis or realize the asset and settle the liability simultaneously.

F. A deferred tax asset shall be recognized for the carryforward of unused tax credits resulting from acquisitions of equipment or technology, research and development expenditures and equity investments to the extent that it is possible that future taxable profit will be available against which the unused tax credits can be utilized.

G. The interim period income tax expense is recognized based on the estimated average annual effective income tax rate expected for the full financial year applied to the pretax income of the interim period, and the related information is disclosed accordingly.

H. If a change in tax rate is enacted or substantively enacted in an interim period, the Group recognizes the effect of the change immediately in the interim period in which the change occurs. The effect of the change on items recognized outside profit or loss is recognized in other comprehensive income or equity while the effect of the change on items recognized in profit or loss is recognized in profit or loss.

(27) Share capital

A. Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new shares or stock options are shown in equity as a deduction, net of tax, from the proceeds.

B. Where the Company repurchases the Company's equity share capital that has been issued, the consideration paid, including any directly attributable incremental costs (net of income taxes) is deducted from equity attributable to the Company's equity holders. Where such shares are subsequently reissued, the difference between their carrying amount and any consideration received, net of any directly attributable incremental transaction costs and the related income tax effects, is included in equity attributable to the Company's equity holders.

(28) Dividends

The distribution of cash dividends was recognized as liabilities in the financial statements after the special resolution of the Board of Directors according to Article 240 of the amended Company Act and the Company's Articles of Incorporation.

(29) Revenue recognition

A. The Group manufactures and sells health foods and cosmetics products. Sales are recognized when control of the products has transferred, being when the products are delivered to the customer who has full discretion over the channel and price to sell the products, and there is no unfulfilled obligation that could affect the customer's acceptance of the products. Delivery occurs when the products have been shipped to the specific location, the risks of obsolescence and loss have been transferred to the customer, and either the customer has accepted the products in accordance with the sales contract, or the Group has objective evidence that all criteria for acceptance have been satisfied.

B. The products are often sold with price break based on aggregate sales. Revenue from these sales is recognized based on the price specified in the contract, net of the estimated price break. Accumulated experience is used to estimate and provide for the price break, using the expected value method, and revenue is only recognized to the extent that it is highly probable that a significant reversal will not occur. The estimation is subject to an assessment at each reporting date. A refund liability is recognized for expected price break payable to customers in relation to sales made until the end of the reporting period.

C. Service revenue

The Group provides health examination services for customers. Revenue from providing services is recognized at a point in time in which the services are rendered.

D. Rental revenue

Rental revenue from an operating lease is recognized in profit or loss on a straight-line basis over the lease term.

(30) Government grants

Government grants are recognized at their fair value only when there is reasonable assurance that the Group will comply with any conditions attached to the grants and the grants will be received.

(31) Operating segments

Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision-maker. The Group's chief operating decision-maker, who is responsible for allocating resources and assessing performance of the operating segments, has been identified as the Board of Directors that makes strategic decisions.

5. CRITICAL ACCOUNTING JUDGEMENTS, ESTIMATES AND KEY SOURCES OF ASSUMPTION UNCERTAINTY

The preparation of these consolidated financial statements requires management to make critical judgements in applying the Group's accounting policies and make critical assumptions and estimates concerning future events. Assumptions and estimates may differ from the actual results and are continually evaluated and adjusted based on historical experience and other factors. Such assumptions and estimates have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year; and the related information is addressed below:

(1) Critical judgements in applying the Group's accounting policies

None.

(2) Critical accounting estimates and assumptions

None.

6. DETAILS OF SIGNIFICANT ACCOUNT

(1) Cash and cash equivalents

	September 30, 2025	December 31, 2024	September 30, 2024
Cash on hand and revolving funds	$ 10,260	$ 12,218	$ 12,777
Checking accounts and demand deposits	2,699,601	3,314,555	3,290,167
Time deposits	3,057,602	2,305,605	2,018,199
	5,767,463	5,632,378	5,321,143
Less: Shown as 'current financial assets at amortized cost'	(234,829)	(860,166)	(665,996)
Less: Shown as 'current financial assets at amortized cost - pledged'	(28,491)	(5,000)	(5,000)
	$ 5,504,143	$ 4,767,212	$ 4,650,147

A. The Group transacts with a variety of financial institutions all with high credit quality to disperse credit risk, so it expects that the probability of counterparty default is remote.

B. As of September 30, 2025, December 31, 2024 and September 30, 2024, the Group recognized time deposits with maturity over 3 months of $263,320, $865,166 and $670,996, respectively, and shown as 'current financial assets at amortized cost'.

C. Details of the Group's cash and cash equivalents pledged to others are provided in Note 8.

(2) Financial assets at fair value through profit or loss

Items	September 30, 2025	December 31, 2024	September 30, 2024
Current items:			
Financial assets mandatorily measured at fair value through profit or loss			
Listed stocks	$ 20,213	$ 39,693	$ 47,282
Valuation adjustment	(7,208)	(8,679)	(8,450)
	$ 13,005	$ 31,014	$ 38,832

A. Amounts recognized in profit or loss in relation to financial assets/liabilities at fair value through profit or loss are listed below:

	Three months ended September 30,	
	2025	2024
Financial assets/liabilities mandatorily measured at fair value through profit or loss		
Equity instruments	($ 496)	($ 4,265)

	Nine months ended September 30,	
	2025	2024
Financial assets/liabilities mandatorily measured at fair value through profit or loss		
Equity instruments	$ 1,471	($ 4,993)

B. The Group has no financial assets at fair value through profit or loss pledged to others as collateral.

C. Information relating to price risk and fair value of financial assets at fair value through profit or loss is provided in Notes 12(2) and (3).

(3) Financial assets at fair value through other comprehensive income

Items	September 30, 2025	December 31, 2024	September 30, 2024
Non-current items:			
Equity instruments			
Listed stocks	$ 12,604	$ 12,604	$ 12,604
Unlisted stocks	22,582	27,054	27,054
	35,186	39,658	39,658
Valuation adjustment	28,339	27,866	22,402
	$ 63,525	$ 67,524	$ 62,060

A. The Group has elected to classify equity investments that are considered to be strategic investments as financial assets at fair value through other comprehensive income. The fair value of such investments amounted to $63,525, $67,524 and $62,060 as at September 30, 2025, December 31, 2024 and September 30, 2024, respectively.

B. Amounts recognized in profit or loss and other comprehensive income in relation to the financial

assets at fair value through other comprehensive income are listed below:

	Three months ended September 30,	
	2025	2024
Equity instruments at fair value through other comprehensive income		
Fair value change recognized in other comprehensive income	$ 3,860	$ -
Cumulative gains (losses) reclassified to retained earnings due to derecognition	$ -	$ -
Dividend income recognized in profit or loss		
Held at end of period	$ 3,684	$ -
Derecognized during the period	-	-
	$ 3,684	$ -

	Nine months ended September 30,	
	2025	2024
Equity instruments at fair value through other comprehensive income		
Fair value change recognized in other comprehensive income	$ 2,540	$ -
Cumulative (losses) gains reclassified to retained earnings due to derecognition	$ 2,067	$ -
Dividend income recognized in profit or loss		
Held at end of period	$ 3,684	$ -
Derecognized during the period	-	-
	$ 3,684	$ -

C. As of September 30, 2025, December 31, 2024 and September 30, 2024, without taking into account any collateral held or other credit enhancements, the maximum exposure to credit risk in respect of the amount that best represents the financial assets at fair value through other comprehensive income held by the Group amounted to $63,525, $67,524 and $62,060, respectively.

D. The Group's financial assets at fair value through other comprehensive income were not pledged to others as collateral.

E. Information relating to credit risk of financial assets at fair value through other comprehensive income is provided in Notes 12(2) and (3).

(4) Financial assets at amortized cost

Items	September 30, 2025	December 31, 2024	September 30, 2024
Current items:			
Time deposits	$ 263,320	$ 865,166	$ 670,996

A. Amounts recognized in profit or loss in relation to financial assets at amortized cost are listed below:

	Three months ended September 30,	
	2025	2024
Interest income	$ 1,411	$ 1,976

	Nine months ended September 30,	
	2025	2024
Interest income	$ 5,776	$ 2,856

B. As at September 30, 2025, December 31, 2024 and September 30, 2024, without taking into account any collateral held or other credit enhancements, the maximum exposure to credit risk in respect of the amount that best represents the financial assets at amortized cost held by the Group was $263,320, $865,166 and $670,996, respectively.

C. Details of the Group's financial assets at amortized cost pledged to others as collateral are provided in Note 8.

D. Information relating to credit risk of financial assets at amortized cost is provided in Note 12(2). The counterparties of the Group's investments in certificates of deposit are financial institutions with high credit quality, so the Group expects that the probability of counterparty default is remote.

(5) Notes and accounts receivable

	September 30, 2025	December 31, 2024	September 30, 2024
Notes receivable	$ 24,519	$ 81,031	$ 17,091
Less: Allowance for uncollectible accounts	-	-	-
	$ 24,519	$ 81,031	$ 17,091
Accounts receivable	$ 1,035,988	$ 873,742	$ 981,823
Less: Allowance for uncollectible accounts	(94,518)	(97,326)	(90,559)
	$ 941,470	$ 776,416	$ 891,264

A. The aging analysis of accounts receivable and notes receivable that were past due but not impaired is as follows:

	September 30, 2025	December 31, 2024	September 30, 2024
Not past due	$ 813,601	$ 692,427	$ 698,883
Up to 30 days	123,081	120,067	105,657
31 to 90 days	23,079	25,675	45,038
Over 90 days	6,228	19,278	58,777
	$ 965,989	$ 857,447	$ 908,355

The above aging analysis was based on past due date.

B. As of September 30, 2025, December 31, 2024 and September 30, 2024, without taking into account any collateral held or other credit enhancements, the maximum exposure to credit risk in respect of the amount that best represents the Group's notes and accounts receivable amounted to

$24,519 , $81,031 and $17,091; $941,470, $776,416 and $891,264, respectively.

C. Information relating to credit risk of accounts receivable and notes receivable is provided in Note 12(2).

(6) Inventories

	September 30, 2025		
	Cost	Allowance for valuation loss	Book value
Raw materials	$ 472,300	($ 59,018)	$ 413,282
Work in progress	136,213	(25,522)	110,691
Finished goods	260,018	(26,806)	233,212
	$ 868,531	($ 111,346)	$ 757,185

	December 31, 2024		
	Cost	Allowance for valuation loss	Book value
Raw materials	$ 496,224	($ 41,775)	$ 454,449
Work in progress	127,783	(10,983)	116,800
Finished goods	319,880	(35,221)	284,659
	$ 943,887	($ 87,979)	$ 855,908

	September 30, 2024		
	Cost	Allowance for valuation loss	Book value
Raw materials	$ 530,623	($ 47,755)	$ 482,868
Work in progress	124,688	(13,901)	110,787
Finished goods	405,725	(40,178)	365,547
	$ 1,061,036	($ 101,834)	$ 959,202

The cost of inventories recognized as expense for the three months and nine months ended September 30, 2025 and 2024, were $971,115, $1,013,443, $2,913,627 and $3,008,155, respectively, including the amounts of ($228), $3,868, $22,541 and $17,111 respectively, that the Group wrote down from cost to net realizable value accounted for as cost of goods sold.

(7) Investments accounted for using equity method

	2025	2024
At January 1	$ 28,182	$ 19,896
Increase in investments accounted for using equity method	17,137	16,687
Disposal of investments accounted for using equity method	(1,020)	-
Share of loss of investments accounted for using equity method	(4,423)	(2,979)
Changes in other equity items	(5,485)	-
At September 30	$ 34,391	$ 33,604

	September 30, 2025	December 31, 2024	September 30, 2024
Associates	$ 34,391	$ 28,182	$ 33,604

(8) Property, plant and equipment

	Land	Buildings and structures	Machinery	Machinery for lease	Office equipment	Others	Unfinished construction and equipment under acceptance	Total
At January 1, 2025								
Cost	$ 957,972	$ 2,521,898	$ 2,571,919	$ 14,980	$ 789,372	$422,938	$ 380,990	$7,660,069
Accumulated depreciation	-	(587,167)	(1,524,606)	(14,980)	(384,819)	(333,577)	-	(2,845,149)
	$ 957,972	$ 1,934,731	$ 1,047,313	$ -	$ 404,553	$ 89,361	$ 380,990	$4,814,920
2025								
At January 1	$ 957,972	$ 1,934,731	$ 1,047,313	$ -	$ 404,553	$ 89,361	$ 380,990	$4,814,920
Additions	-	2,188	25,565	-	8,464	22,223	94,099	152,539
Disposals	(1,785)	(6,543)	(13,445)	-	(557)	(444)	-	(22,774)
Transfers	-	-	30,922	-	2,542	4,033	28,960	66,457
Depreciation charge	-	(58,900)	(197,568)	-	(58,821)	(27,092)	-	(342,381)
Net exchange differences	-	(18,392)	(19,988)	-	(3,658)	(911)	-	(42,949)
At September 30	$ 956,187	$ 1,853,084	$ 872,799	$ -	$ 352,523	$ 87,170	$ 504,049	$4,625,812
At September 30, 2025								
Cost	$ 956,187	$ 2,490,798	$ 2,511,847	$ 14,980	$ 792,164	$440,659	$ 504,049	$7,710,684
Accumulated depreciation	-	(637,714)	(1,639,048)	(14,980)	(439,641)	(353,489)	-	(3,084,872)
	$ 956,187	$ 1,853,084	$ 872,799	$ -	$ 352,523	$ 87,170	$ 504,049	$4,625,812

	Land	Buildings and structures	Machinery	Machinery for lease	Office equipment	Others	Unfinished construction and equipment under acceptance	Total
At January 1, 2024								
Cost	$ 957,972	$ 2,419,408	$ 2,371,004	$ 35,982	$ 798,239	$421,919	$ 392,873	$7,397,397
Accumulated depreciation	-	(502,254)	(1,270,207)	(35,982)	(328,918)	(319,566)	-	(2,456,927)
	$ 957,972	$ 1,917,154	$ 1,100,797	$ -	$ 469,321	$102,353	$ 392,873	$4,940,470
2024								
At January 1	$ 957,972	$ 1,917,154	$ 1,100,797	$ -	$ 469,321	$102,353	$ 392,873	$4,940,470
Additions	-	2,460	25,872	-	7,815	16,554	6,572	59,273
Disposals	-	(365)	(483)	-	(58)	(343)	-	(1,249)
Transfers	-	-	40,051	-	7,748	9,730	(25,897)	31,632
Depreciation charge	-	(61,318)	(206,445)	-	(61,957)	(32,207)	-	(361,927)
Net exchange differences	-	12,388	10,972	-	1,850	545	-	25,755
At September 30	$ 957,972	$ 1,870,319	$ 970,764	$ -	$ 424,719	$ 96,632	$ 373,548	$4,693,954
At September 30, 2024								
Cost	$ 957,972	2,439,450	$ 2,430,920	$ 35,982	$ 789,678	$422,231	$ 373,548	$7,449,781
Accumulated depreciation	-	(569,131)	(1,460,156)	(35,982)	(364,959)	(325,599)	-	(2,755,827)
	$ 957,972	$ 1,870,319	$ 970,764	$ -	$ 424,719	$ 96,632	$ 373,548	$4,693,954

Information about the property, plant and equipment that were pledged to others as collateral is provided in Note 8.

(9) Leasing arrangements-lessee

A. The Group leases various assets including land, buildings and business vehicles. Rental contracts are typically made for periods of 2 to 50 years. Lease terms are negotiated on an individual basis and contain a wide range of different terms and conditions. The lease agreements do not impose covenants, but leased assets may not be used as security for borrowing purposes.

B. The carrying amount of right-of-use assets and the depreciation charge are as follows:

	September 30, 2025	December 31, 2024	September 30, 2024
	Carrying amount	Carrying amount	Carrying amount
Land	$ 24,854	$ 26,584	$ 27,028
Buildings	165,531	209,802	229,987
	$ 190,385	$ 236,386	$ 257,015

	Three months ended September 30,	
	2025	2024
	Depreciation charge	Depreciation charge
Land	$ 163	$ 177
Buildings	17,103	18,293
	$ 17,266	$ 18,470

	Nine months ended September 30,	
	2025	2024
	Depreciation charge	Depreciation charge
Land	$ 506	$ 522
Buildings	52,630	53,966
	$ 53,136	$ 54,488

C. In March 2013, the Group signed a land use right contract with Shanghai Municipal Planning, Land and Resources Administration for use of the land in Jinshan District, Shanghai City with a term of 50 years. All rentals had been paid on the contract date.

D. For the three months and nine months ended September 30, 2025 and 2024, the additions to right-of-use amounted to $183, $4,055, $12,982 and $112,601, respectively.

E. The information on profit and loss accounts relating to lease contracts is as follows:

	Three months ended September 30,	
	2025	2024
Items affecting profit or loss		
Interest expense on lease liabilities	$ 1,245	$ 1,485
Expense on short-term lease contracts	$ 14,530	$ 12,690
Expense on leases of low-value assets	$ 400	$ 666
Gain or loss on lease modification	$ -	$ -

	Nine months ended September 30,	
	2025	2024
Items affecting profit or loss		
Interest expense on lease liabilities	$ 4,069	$ 4,508
Expense on short-term lease contracts	$ 42,921	$ 38,450
Expense on leases of low-value assets	$ 1,253	$ 1,420
Gain or loss on lease modification	$ -	$ -

F. For the three months and nine months ended September 30, 2025 and 2024, the Group's total cash outflow for leases amounted to $37,311, $32,705, $101,181 and $96,828, respectively.

(10) Intangible assets

	Goodwill	Trademarks	Customer relation	Software	Royalty	Others	Total
At January 1, 2025							
Cost	$ 299,689	$ 132,821	$ 220,000	$ 36,740	$ 7,400	$ 143,856	$ 840,506
Accumulated amortization	-	(25,983)	(77,000)	(33,005)	(6,808)	(54,689)	(197,485)
	$ 299,689	$ 106,838	$ 143,000	$ 3,735	$ 592	$ 89,167	$ 643,021
2025							
At January 1	$ 299,689	$ 106,838	$ 143,000	$ 3,735	$ 592	$ 89,167	$ 643,021
Additions— acquired separately	-	-	-	1,656	-	-	1,656
Amortization charge	-	(5,118)	(16,500)	(2,011)	(196)	(10,024)	(33,849)
Net exchange differences	-	-	-	(31)	-	(117)	(148)
At September 30	$ 299,689	$ 101,720	$ 126,500	$ 3,349	$ 396	$ 79,026	$ 610,680
At September 30, 2025							
Cost	$ 299,689	$ 132,812	$ 220,000	$ 38,330	$ 7,400	$ 143,738	$ 841,969
Accumulated amortization	-	(31,092)	(93,500)	(34,981)	(7,004)	(64,712)	(231,289)
	$ 299,689	$ 101,720	$ 126,500	$ 3,349	$ 396	$ 79,026	$ 610,680

	Goodwill	Trademarks	Customer relation	Software	Royalty	Others	Total
At January 1, 2024							
Cost	$ 299,689	$ 132,720	$ 220,000	$ 36,358	$ 7,400	$ 143,817	$ 839,984
Accumulated amortization	-	(19,074)	(55,000)	(26,962)	(6,548)	(41,251)	(148,835)
	$ 299,689	$ 113,646	$ 165,000	$ 9,396	$ 852	$ 102,566	$ 691,149
2024							
At January 1	$ 299,689	$ 113,646	$ 165,000	$ 9,396	$ 852	$ 102,566	$ 691,149
Additions— acquired separately	-	95	-	330	-	-	425
Amortization charge	-	(5,175)	(16,500)	(4,678)	(196)	(10,089)	(36,638)
Net exchange differences	-	4	-	34	-	67	105
At September 30	$ 299,689	$ 108,570	$ 148,500	$ 5,082	$ 656	$ 92,544	$ 655,041
At September 30, 2024							
Cost	$ 299,689	$ 132,824	$ 220,000	$ 36,728	$ 7,400	$ 143,884	$ 840,525
Accumulated amortization	-	(24,254)	(71,500)	(31,646)	(6,744)	(51,340)	(185,484)
	$ 299,689	$ 108,570	$ 148,500	$ 5,082	$ 656	$ 92,544	$ 655,041

A. Details of amortization on intangible assets are as follows:

	Three months ended September 30,			
	2025		2024	
Overhead	$	2,832	$	3,728
Selling expenses		720		360
General and administrative expenses		6,038		6,913
Research and development expenses		1,407		1,021
	$	10,997	$	12,022

	Nine months ended September 30,			
	2025		2024	
Overhead	$	10,053	$	10,376
Selling expenses		1,910		1,442
General and administrative expenses		17,627		21,855
Research and development expenses		4,259		2,965
	$	33,849	$	36,638

B. Goodwill is allocated as follows to the Group's cash-generating units identified according to operating segment:

	September 30, 2025		September 30, 2024	
Taiwan	$	299,689	$	299,689

(11) Impairment of non-financial assets

Goodwill is allocated to the Group's cash-generating units identified according to operating segment. The recoverable amount of all cash-generating units has been determined based on value-in-use calculations. These calculations use pre-tax cash flow projections based on financial budgets approved by the management covering a five-year period. As of December 31, 2024 and 2023, the recoverable amount of the Group's cash-generating units calculated using the value-in use exceeded their carrying amount, so goodwill was not impaired. The key assumptions used for value-in-use calculations are as follows:

	2024	2023
	Discount rate	Discount rate
Taiwan	7.97%	8.25%

(12) Short-term borrowings

Type of Borrowings	September 30, 2025	Interest rate range	Collateral
Bank borrowings			
Unsecured borrowings	$ 1,512,520	1.67%~1.86%	None

Type of Borrowings	December 31, 2024	Interest rate range	Collateral
Bank borrowings			
Unsecured borrowings	$ 429,888	3.65%	None

Type of borrowings	September 30, 2024	Interest rate range	Collateral
Bank borrowings			
Unsecured borrowings	$ 504,208	1.79%~2%	None

(13) Financial liabilities at fair value through profit or loss

Items	September 30, 2025	December 31, 2024	September 30, 2024
Current items:			
Financial liabilities held for trading			
Derivative instruments	$ 1,136	$ -	$ -

A. Amounts recognized in profit or loss and other comprehensive income in relation to financial liabilities at fair value through profit or loss are as follows:

	Three months ended September 30,	
	2025	2024
Net gains (losses) recognized in profit or loss		
Financial liabilities held for trading		
Derivative instruments	($ 12,199)	$ -

	Nine months ended September 30,	
	2025	2024
Net gains (losses) recognized in profit or loss		
Financial liabilities held for trading		
Derivative instruments	($ 4,565)	$ -

B. Explanations of the transactions and contract information in respect of derivative financial liabilities that the Group does not adopt hedge accounting are as follows:

Derivative financial liabilities		September 30, 2025 Contract amount (Notional principal)	Contract period		September 30, 2024 Contract amount (Notional principal)	Contract period
Current items:						
Forward foreign exchange contracts	USD	$ 1,000	114.9.12 ~114.10.3	-	$ -	
Forward foreign exchange contracts	USD	1,000	114.9.12 ~114.11.7	-	-	
Forward foreign exchange contracts	USD	1,000	114.9.12 ~114.11.7	-	-	
Forward foreign exchange contracts	EUR	670	114.9.12 ~114.11.7	-	-	

The Group entered into forward foreign exchange contracts to (buy) sell forward foreign transactions to hedge exchange rate risk of (import) export proceeds. However, these forward foreign exchange contracts are not accounted for under hedge accounting.

C. Information relating to price risk and fair value of financial liabilities at fair value through profit or loss is provided in Notes 12(2) and (3).

(14) Other payables

	September 30, 2025	December 31, 2024	September 30, 2024
Employee bonus payable	$ 416,345	$ 392,619	$ 392,450
Salaries and bonuses payable	217,700	196,765	233,845
Tax payables	13,128	11,390	8,274
Payable on machinery and equipment	8,967	6,491	8,251
Other payables	124,010	99,116	155,625
	$ 780,150	$ 706,381	$ 798,445

(15) Pensions

A.(a) The Company and its domestic subsidiaries have a defined benefit pension plan in accordance with the Labor Standards Law, covering all regular employees' service years prior to the enforcement of the Labor Pension Act on July 1, 2005 and service years thereafter of employees who chose to continue to be subject to the pension mechanism under the Law. Under the defined benefit pension plan, two units are accrued for each year of service for the first 15 years and one unit for each additional year thereafter, subject to a maximum of 45 units. Pension benefits are based on the number of units accrued and the average monthly salaries and wages of the last 6 months prior to retirement. The Company and its domestic subsidiaries contribute monthly an amount equal to 2% of the employees' monthly salaries and wages to the retirement fund deposited with Bank of Taiwan, the trustee, under the name of the

independent retirement fund committee. Also, the Company and its domestic subsidiaries would assess the balance in the aforementioned labor pension reserve account by December 31, every year. If the account balance is insufficient to pay the pension calculated by the aforementioned method to the employees expected to qualify for retirement in the following year, the Company and its domestic subsidiaries will make contributions for the deficit by next March.

(b) There were no pension costs under the defined contribution pension plans of the Group for the three months and nine months ended September 30, 2025 and 2024.

(c) Expected contributions to the defined benefit pension plans of the Group for the year ending December 31, 2025 amount to $1.

B.(a) Effective July 1, 2005, the Company and its domestic subsidiaries have established a defined contribution pension plan (the "New Plan") under the Labor Pension Act (the "Act"), covering all regular employees with R.O.C. nationality. Under the New Plan, the Company and its domestic subsidiaries contribute monthly an amount based on 6% of the employees' monthly salaries and wages to the employees' individual pension accounts at the Bureau of Labor Insurance. The benefits accrued are paid monthly or in lump sum upon termination of employment.

(b)The Group's mainland China subsidiaries have a defined contribution plan. Monthly contributions to an independent fund administered by the government in accordance with the pension regulations in the People's Republic of China (PRC) are based on certain percentage of employees' monthly salaries and wages. The contribution percentage for the three months and nine months ended September 30, 2025 and 2024, were both 16%. Other than the monthly contributions, the Group has no further obligations.

(c) The pension costs under the defined contribution pension plans of the Group for the three months and nine months ended September 30, 2025 and 2024 were $14,862, $14,198, $40,745 and $43,235, respectively.

(16) Long-term borrowings

Type of borrowings	Borrowing period and repayment term	Interest rate range	Collateral	September 30, 2025
Long-term bank borrowings				
Unsecured borrowings	Borrowing period is from March 3, 2020, to January 15, 2028; interest is repayable monthly.	1.875%	None	$ 48,317
Unsecured borrowings	Borrowing period is from August 14, 2024, to August 14, 2027; interest is repayable monthly.	1.98%	None	479,559
Secured borrowings	Borrowing period is from March 29, 2023, to September 14, 2035; interest is repayable monthly.	2.13%	Factory	561,171
				1,089,047
Less:Current portion				(80,275)
				$ 1,008,772

Type of borrowings	and repayment term	range	Collateral	December 31, 2024
Long-term bank borrowings				
Unsecured borrowings	Borrowing period is from March 3, 2020, to January 15, 2028; interest is repayable monthly.	1.875%	None	$ 70,359
Unsecured borrowings	Borrowing period is from August 14, 2024, to August 14, 2027; interest is repayable monthly.	1.98%	None	500,000
Secured borrowings	Borrowing period is from March 29, 2023, to August 14, 2035; interest is repayable monthly.	2.13%	Factory	598,639
				1,168,998
Less:Current portion				(79,469)
				$ 1,089,529

Type of borrowings	Borrowing period and repayment term	Interest rate range	Collateral	September 30, 2024
Long-term bank borrowings				
Unsecured borrowings	Borrowing period is from March 3, 2020, to January 15, 2028; interest is repayable monthly.	1.875%	None	$ 77,703
Unsecured borrowings	Borrowing period is from August 14, 2024, to August 14, 2027; interest is repayable monthly.	1.98%	None	500,000
Secured borrowings	Borrowing period is from March 29, 2023, to August 14, 2038; interest is repayable monthly.	2.13%	Land and Building	610,996
				1,188,699
Less: Current portion				(79,203)
				$ 2,298,195

(17) Share-based payment

A. For the nine months ended September 30, 2025 and 2024, the Group's share-based payment arrangements were as follows:

Type of arrangement	Issuance date	Quantity granted	Contract period	Vesting conditions
Employee stock options	2018.05.15	2,000	6 years	Employees with 2 service years are entitled to 40% Employees with 3 service years are entitled to 80% Employees with 4 service years are entitled to 100%
Employee stock options	2021.11.03	2,630	6 years	Employees with 2 service years are entitled to 40% Employees with 3 service years are entitled to 80% Employees with 4 service years are entitled to 100%
Employee stock options	2022.08.03	770	6 years	Employees with 2 service years are entitled to 40% Employees with 3 service years are entitled to 80% Employees with 4 service years are entitled to 100%

The restricted stocks issued by the Group cannot be transferred during the vesting period, but voting right and dividend right are not restricted on these stocks. Employees are required to return the stocks but not required to return the dividends received if they resign during the vesting period. The share-based payment arrangements above are settled by equity.

B. Details of the share-based payment arrangements are as follows:

	Nine months ended September 30,			
	2025		2024	
	No. of options	Weighted-average exercise price (in dollars)	No. of options	Weighted-average exercise price (in dollars)
Options outstanding at January 1	-	$ -	1,385	$ 448
Options expired	-	-	(1,385)	448
Options outstanding at the end of the period	-	$ -	-	$ 448
Options exercisable at the end of the period	-	$ -	-	$ 448

	Nine months ended September 30,			
	2025		2024	
	No. of options	Weighted-average exercise price (in dollars)	No. of options	Weighted-average exercise price (in dollars)
Options outstanding at January 1	1,872	$ 67.91	2,762	$ 49.17
Options exercised	(4)	33.10	(206)	38.85
Options outstanding at the end of the period	1,868	$ 68.06	2,556	$ 50.00
Options exercisable at the end of the period	1,683	$ 39.85	839	$ 39.46

C. The expiry date and exercise price of stock options outstanding at balance sheet date are as follows:

		September 30, 2025		December 31, 2024		September 30, 2024	
Issue date approved	Expiry date	No. of shares (in thousands)	Exercise price (in dollars)	No. of shares (in thousands)	Exercise price (in dollars)	No. of shares (in thousands)	Exercise price (in dollars)
2018.05.15	2024.05.14	-	$ -	-	$ 448	-	$ 448
2021.11.03	2027.11.02	1,379	50.8	1,379	50.8	2,630	50.8
2022.08.03	2028.08.03	489	41.2	493	41.2	770	41.2

D. The fair value of stock options granted on grant date is measured using the Black-Scholes option-pricing model. Relevant information is as follows:

Type of arrangement	Issuance date	Stock price (in dollars)	Exercise price (in dollars)	Expected price volatility (%)	Expected option life (year)	Expected dividends	Risk-free interest rate(%)	Fair value per unit (in dollars)
Employee stock options	2018.05.15	$ 440.00	$ 448	26.10~30.25	5.75	-	0.5636~0.6814	$ 63.16~106.15
Employee stock options	2021.11.03	$ 50.80	$ 50.80	43.63~47.84	5.00	-	0.41~0.44	$ 18.94~19.37
Employee stock options	2022.08.03	$ 41.20	$ 41.20	45.89~48.46	5.00	-	1.00~1.03	$ 15.11~16.98

Note: Expected price volatility rate was estimated by using the stock prices of the most recent period with length of this period approximate to the length of the stock options' expected life, and the standard deviation of return on the stock during this period.

E. Expenses incurred on share-based payment transactions are shown below:

	Three months ended September 30,	
	2025	2024
Equity-settled	$ 667	$ 1,659
	Nine months ended September 30,	
	2025	2024
Equity-settled	$ 2,004	$ 6,268

F. On June 26, 2019, the Company issued 900 thousand shares of employee restricted ordinary shares as approved by the regulatory authority. The exercise price is $10 (in dollars) per share and the fair value is determined based on the closing price of $282 (in dollars) at the grant date less the exercise price of $10 (in dollars). The information relating to the restrictions on the shareholder's right is provided in the aforementioned details. Other than these restrictions, the rights and obligations of these shares issued are the same as other issued ordinary shares.

(18) Share capital

A. As of September 30, 2025, the Company's authorized capital was $3,000,000, and the paid-in capital was $1,177,288, with a par value of $10 (in dollars) per share. All proceeds from shares issued have been collected.

B. Treasury shares

(a) Reason for share reacquisition and movements in the number of the Company's treasury shares are as follows:

		September 30, 2025	
Name of company holding the shares	Reason for reacquisition	Number of shares	Carrying amount(Note)
Subsidiary-MAXIGEN BIOTECH INC.	To improve the group's operational efficiency	2,531,000	$ 500,084
Subsidiary-GENE & NEXT INC.	To improve the group's operational efficiency	5,015,000	693,431
Less:Non-controlling interest			(759,321)
			$ 434,194

		December 31, 2024	
Name of company holding the shares	Reason for reacquisition	Number of shares	Carrying amount(Note)
The Company	To be reissued to employees	532,000	$ 118,787
Subsidiary-MAXIGEN BIOTECH INC.	To improve the group's operational efficiency	2,531,000	500,084
Subsidiary-GENE & NEXT INC.	To improve the group's operational efficiency	4,500,000	623,438
Less:Non-controlling interest			(732,361)
			$ 509,948

		September 30, 2024	
Name of company holding the shares	Reason for reacquisition	Number of shares	Carrying amount
The Company	To be reissued to employees	532,000	$ 118,787
Subsidiary-MAXIGEN BIOTECH INC.	To improve the group's operational efficiency	2,531,000	500,084
Subsidiary-GENE & NEXT INC.	To improve the group's operational efficiency	4,500,000	623,438
Less:Non-controlling interest			(747,876)
			$ 494,433

Note：The Company’s subsidiary - MAXIGEN BIOTECH INC. and GENE & NEXT INC. are both a subsidiary of the Company with substantial control, but the Company’s shareholding in it is 28.26% and 42.23% respectively but not up to 50%. Therefore, the company's repurchase of the Company’s stock is not subject to the Company Law Section 167 Restrictions.

(b) Pursuant to the R.O.C. Securities and Exchange Act, the number of shares bought back as treasury share should not exceed 10% of the number of the Company’s issued and outstanding shares and the amount bought back should not exceed the sum of retained earnings, paid-in capital in excess of par value and realized capital surplus.

(c) Pursuant to the R.O.C. Securities and Exchange Act, treasury shares should not be pledged as collateral and is not entitled to dividends before it is reissued.

(d) Pursuant to the R.O.C. Securities and Exchange Act, treasury shares should be reissued to the employees within five years from the reacquisition date and shares not reissued within

the five-year period are to be retired. Treasury shares to enhance the Company's credit rating and the stockholders' equity should be retired within six months of acquisition.

(19) Capital surplus

Pursuant to the R.O.C. Company Act, capital surplus arising from paid-in capital in excess of par value on issuance of common stocks and donations can be used to cover accumulated deficit or to issue new stocks or cash to shareholders in proportion to their share ownership, provided that the Company has no accumulated deficit. Further, the R.O.C. Securities and Exchange Act requires that the amount of capital surplus to be capitalized mentioned above should not exceed 10% of the paid-in capital each year. Capital surplus should not be used to cover accumulated deficit unless the legal reserve is insufficient.

(20) Retained earnings

A. Under the Company's Articles of Incorporation, the current year's earnings, if any, shall first be used to pay all taxes and offset prior years' operating losses and then 10% of the remaining amount shall be set aside as legal reserve. The remainder, if any, to be retained or to be appropriated shall be resolved by the stockholders at the stockholders' meeting.

In accordance with Article 240 of the Company Act, the Board of Directors is authorized by the Company to resolve the distribution of dividends and bonuses or legal reserve and capital reserve, in whole or in part, in accordance with Article 241 of the Company Act in the form of cash by a resolution adopted by the majority vote at its meeting attended by two-thirds of the total number of directors, and then reported to the shareholders. The aforesaid requirement that resolution shall be resolved at the shareholders' meeting is not applicable.

B. The Company's dividend policy is summarized below: as the Company operates in a volatile business environment and is in the stable growth stage, the residual dividend policy is adopted taking into consideration the Company's financial structure, operating results and future expansion plans, and cash dividends shall account for at least 10% of the total dividends distributed. However, if the Company has sufficient retained earnings and capital, the Company may increase cash dividends in proportion to total dividends.

C. Except for covering accumulated deficit or issuing new stocks or cash to shareholders in proportion to their share ownership, the legal reserve shall not be used for any other purpose. The use of legal reserve for the issuance of stocks or cash to shareholders in proportion to their share ownership is permitted, provided that the distribution of the reserve is limited to the portion in excess of 25% of the Company's paid-in capital.

D. Special reserve

(a) In accordance with the regulations, the Company shall set aside special reserve from the debit balance on other equity items at the balance sheet date before distributing earnings. When debit balance on other equity items is reversed subsequently, the reversed amount could be included in the distributable earnings.

(b) The amounts previously set aside by the Company as special reserve on initial application of IFRSs according to Order No. Financial-Supervisory-Securities-Corporate-1090150022, dated March 31, 2021, shall be reversed proportionately when the relevant assets are used, disposed of or reclassified subsequently.

E. On May 9, 2024, the shareholders at the shareholders' meeting approved the distribution of dividends from the 2023 earnings in the amount of $824,102, with cash dividends of $7 (in dollars) per share. On June 26, 2025, the Board of Directors proposed the distribution of dividends from the 2024 earnings in the amounts of $835,875 and $341,414, with cash dividends of $7.1 (in dollars) per common share from the earnings and an additional cash dividend of $2.9 (in dollars) per common share from the capital reserve - premium on common stock.

(21) Other equity items

	2025		
	Unrealized gains (losses) on valuation	Currency translation	Total
At January 1	($ 2,741)	($ 151,239)	($ 153,980)
Currency translation differences	-	(193,756)	(193,756)
Revaluation - gross	2,540	-	2,540
Revaluation transferred to retained earnings	(2,067)	-	(2,067)
At September 30	($ 2,268)	($ 344,995)	($ 347,263)

	2024		
	Unrealized gains (losses) on valuation	Currency translation	Total
At January 1	($ 3,152)	($ 280,381)	($ 283,533)
Currency translation differences	-	162,385	162,385
Revaluation - gross	(906)	-	(906)
At September 30	($ 4,058)	($ 117,996)	($ 122,054)

(22) Operating revenue

	Three months ended September 30,	
	2025	2024
Revenue from contracts with customers	$ 1,740,037	$ 1,804,527

	Nine months ended September 30,	
	2025	2024
Revenue from contracts with customers	$ 5,123,227	$ 5,293,839

A. Disaggregation of revenue from contracts with customers

The Group derives revenue from the transfer of goods and services at a point in time in the following major geographical regions:

Three months ended September 30, 2025	Europe and America region	Asia Pacific region	Total
Segment revenue	$ 1,105,809	$ 1,203,255	$ 2,309,064
Inter-segment revenue	(359,001)	(210,026)	($ 569,027)
Revenue from external customer contracts	$ 746,808	$ 993,229	$ 1,740,037

Three months ended September 30, 2024	Europe and America region	Asia Pacific region	Total
Segment revenue	$ 1,167,932	$ 1,353,617	$ 2,521,549
Inter-segment revenue	(400,462)	(316,560)	(717,022)
Revenue from external customer contracts	$ 767,470	$ 1,037,057	$ 1,804,527

Nine months ended September 30, 2025	Europe and America region	Asia Pacific region	Total
Segment revenue	$ 3,142,163	$ 3,578,107	$ 6,720,270
Inter-segment revenue	(963,675)	(633,368)	(1,597,043)
Revenue from external customer contracts	$ 2,178,488	$ 2,944,739	$ 5,123,227

Nine months ended September 30, 2024	Europe and America region	Asia Pacific region	Total
Segment revenue	$ 3,152,190	$ 4,271,689	$ 7,423,879
Inter-segment revenue	(1,141,043)	(988,997)	(2,130,040)
Revenue from external customer contracts	$ 2,011,147	$ 3,282,692	$ 5,293,839

Timing of revenue mentioned above is all at a point in time.

B. Contract assets and liabilities

As of September 30, 2025, December 31, 2024, September 30, 2024, and January 1, 2024, the Group has not recognized any revenue-related contract assets, while the Group has recognized contract liabilities below:

	September 30, 2025	December 31, 2024	September 30, 2024	January 1, 2024
Contract liabilities – advance sales receipts	$ 405,282	$ 552,566	$ 583,312	$ 496,528

(a) Significant changes in contract assets and liabilities: None.

(b) Revenue recognized that was included in the contract liability balance at the beginning of the period:

	Three months ended September 30,	
	2025	2024
Revenue recognized that was included in the contract liability balance at the beginning of the period		
Advance sales receipts	$ 31,765	$ 6,436

	Nine months ended September 30,	
	2025	2024
Revenue recognized that was included in the contract liability balance at the beginning of the period		
Advance sales receipts	$ 276,544	$ 310,540

(23) Interest income

	Three months ended September 30,	
	2025	2024
Interest income from bank deposits (Note)	$ 15,055	$ 16,473

	Nine months ended September 30,	
	2025	2024
Interest income from bank deposits (Note)	$ 51,669	$ 51,988

Note: Including interest income from financial assets measured at amortized cost.

(24) Other income

	Three months ended September 30,	
	2025	2024
Dividend income	$ 4,142	$ 3,164
Subsidy income	(69)	25
Other income - others	5,054	5,663
Gains on write-off of past due payable	32,219	-
	$ 41,346	$ 8,852

	Nine months ended September 30,	
	2025	2024
Dividend income	$ 4,142	$ 3,164
Subsidy income	7,541	553
Other income - others	13,645	16,118
Gains on write-off of past due payable	52,353	-
	$ 77,681	$ 19,835

(25) Other gains and losses

	Three months ended September 30,	
	2025	2024
Losses on disposal of property, plant and equipment	($ 3,908)	($ 336)
(Losses) gains on disposal of investments	(151)	176
Foreign exchange gains (losses)	23,438	(11,494)
Net losses on financial assets at fair value through profit	(12,695)	(524)
Miscellaneous disbursements	(234)	(14)
	$ 6,450	($ 12,192)

	Nine months ended September 30,	
	2025	2024
Gains (losses) on disposal of property, plant and equipment	$ 2,244	($ 506)
Losses on disposal of investments	(1,725)	(468)
Foreign exchange (losses) gains	(31,637)	53,878
Net losses on financial assets at fair value through profit or loss	(3,094)	(1,252)
Miscellaneous disbursements	(5,027)	(931)
	($ 39,239)	$ 50,721

(26) Finance costs

	Three months ended September 30,	
	2025	2024
Interest expense		
Bank borrowings	$ 9,565	$ 10,068
Interest from lease liabilities	1,245	1,485
Imputed interest on rent deposit	-	3
	$ 10,810	$ 11,556

	Nine months ended September 30,	
	2025	2024
Interest expense		
Bank borrowings	$ 31,405	$ 28,478
Interest from lease liabilities	4,069	4,508
Imputed interest on rent deposit	-	9
	$ 35,474	$ 32,995

(27) Expenses by nature

	Three months ended September 30,	
	2025	2024
Employee benefit expense	$ 333,645	$ 363,922
Depreciation charges on property, plant and equipment and depreciation charges on right-of-use assets	128,950	135,677
Operating lease payments	14,930	13,356
Amortization charges on intangible assets	10,997	12,022

	Nine months ended September 30,	
	2025	2024
Employee benefit expense	$ 1,035,609	$ 1,111,999
Depreciation charges on property, plant and equipment and depreciation charges on right-of-use assets	395,517	416,415
Operating lease payments	44,174	39,870
Amortization charges on intangible assets	33,849	36,638

(28) Employee benefit expense

	Three months ended September 30,	
	2025	2024
Wages and salaries	$ 276,457	$ 303,749
Employee stock options (Note)	667	1,659
Labor and health insurance fees	29,751	30,114
Pension costs	14,862	14,198
Other personnel expenses	11,908	14,202
	$ 333,645	$ 363,922

	Nine months ended September 30,	
	2025	2024
Wages and salaries	$ 875,151	$ 932,057
Employee stock options (Note)	2,004	6,268
Labor and health insurance fees	82,513	89,531
Pension costs	40,745	43,235
Other personnel expenses	35,196	40,908
	$ 1,035,609	$ 1,111,999

Note: It was equity-settled.

A. In accordance with the Articles of Incorporation of the Company, a ratio of distributable profit of the current year, after covering accumulated losses, shall be distributed as employees' compensation and directors' and supervisors' remuneration. The ratio shall be 5%~15% for employees' compensation (with not less than 25% distributed to grassroots employees) and shall not be higher than 3% for directors' and supervisors' remuneration.

B. For the three months and nine months ended September 30, 2025 and 2024, employees' compensation was accrued at $6,650, $17,845, $49,738 and $57,148, respectively; while directors' and supervisors' remuneration was accrued at $1,050, $1,050, $3,150 and $3,150, respectively. The aforementioned amounts were recognized in salary expenses.

C. The employees' compensation and directors' and supervisors' remuneration were estimated and accrued based on 5%~15% and not be higher than 3% of distributable profit of current year for the nine months ended September 30, 2025 and 2024.

D. Employees' compensation and directors' and supervisors' remuneration for 2024 amounting to $83,119 and $4,100, respectively, as resolved at the meeting of Board of Directors were in agreement with those amounts recognized in the 2024 financial statements, and the employees' compensation was distributed in the form of cash.

E. Information about employees' compensation and directors' and supervisors' remuneration of the Company as resolved by the Board of Directors will be posted in the "Market Observation Post System" at the website of the Taiwan Stock Exchange.

(29) Income tax

A. Income tax expense

Components of income tax expense:

	Three months ended September 30,	
	2025	2024
Current tax:		
Current tax on profits for the period	$ 55,620	$ 57,769
Effect from investment tax credits	-	(3,023)
Prior year income tax over estimation	-	(281)
Total current tax	55,620	54,465
Deferred tax:		
Origination and reversal of temporary differences	4,602	(976)
Total deferred tax	4,602	(976)
Income tax expense	$ 60,222	$ 53,489

	Nine months ended September 30,	
	2025	2024
Current tax:		
Current tax on profits for the period	$ 146,768	$ 140,748
Effect from investment tax credits	(42,225)	(43,864)
Prior year income tax under (over) estimation	11,516	(14,105)
Total current tax	116,059	82,779
Deferred tax:		
Origination and reversal of temporary differences	(15,784)	4,769
Total deferred tax	(15,784)	4,769
Income tax expense	$ 100,275	$ 87,548

B. The Company's income tax returns through 2020 have been assessed and approved by the Tax Authority.

(30) Earnings per share

	Three months ended September 30, 2025		
	Amount after tax	Weighted average number of ordinary shares outstanding (shares in thousands)	Earnings per share (in dollars)
Basic earnings per share			
Profit attributable to the parent	$ 274,271	109,631	$ 2.50
Diluted earnings per share			
Profit attributable to ordinary shareholders of the parent	$ 274,271		
Assumed conversion of all dilutive potential ordinary shares			
Employees' compensation	-	56	
Shareholders of the parent plus assumed conversion of all dilutive potential ordinary shares	$ 274,271	109,687	$ 2.50

	Three months ended September 30, 2024		
	Amount after tax	Weighted average number of ordinary shares outstanding (shares in thousands)	Earnings per share (in dollars)
Basic earnings per share			
Profit attributable to the parent	$ 163,250	110,698	$ 1.47
Diluted earnings per share			
Profit attributable to ordinary shareholders of the parent	$ 163,250		
Assumed conversion of all dilutive potential ordinary shares			
Employees' compensation	-	130	
Employee stock options	-	14	
Shareholders of the parent plus assumed conversion of all dilutive potential ordinary shares	$ 163,250	110,842	$ 1.47

	Nine months ended September 30, 2025		
	Amount after tax	Weighted average number of ordinary shares outstanding (shares in thousands)	Earnings per share (in dollars)
Basic earnings per share			
Profit attributable to the parent	$ 648,913	110,142	$ 5.89
Diluted earnings per share			
Profit attributable to ordinary shareholders of the parent	$ 648,913		
Assumed conversion of all dilutive potential ordinary shares			
Employees' compensation	-	570	
Shareholders of the parent plus assumed conversion of all dilutive potential ordinary shares	$ 648,913	110,712	$ 5.86

	Nine months ended September 30, 2024		
	Amount after tax	Weighted average number of ordinary shares outstanding (shares in thousands)	Earnings per share (in dollars)
Basic earnings per share			
Profit attributable to the parent	$ 561,618	112,422	$ 5.00
Diluted earnings per share			
Profit attributable to ordinary shareholders of the parent	$ 561,618		
Assumed conversion of all dilutive potential ordinary shares			
Employees' compensation	-	624	
Employee stock options	-	14	
Shareholders of the parent plus assumed conversion of all dilutive potential ordinary shares	$ 561,618	113,060	$ 4.97

(31) Transactions with non-controlling interest

Acquisition of additional equity interest in a subsidiary

On June 30, 2025, the Group acquired an additional 2.84% of shares of its subsidiary—MAXIGEN BIOTECH INC. for a total cash consideration of $117,763. The carrying amount of non-controlling interest in MAXIGEN BIOTECH INC. was $38,834 at the acquisition date. This transaction resulted in a decrease in the non-controlling interest by $117,763 and a decrease in the equity attributable to owners of the parent by $78,929. The effect of changes in interests in 2025 on the equity attributable to owners of the parent is shown below:

	Nine months ended September 30,	
	2025	2024
Carrying amount of non-controlling interest acquired	$ 38,834	$ -
Consideration paid to non-controlling interest	(117,763)	-
Capital surplus - difference between proceeds on actual acquisition of or disposal of equity interest in a subsidiary and its carrying amount	($ 78,929)	$ -

(32) Supplemental cash flow information

Investing activities with partial cash payments

	Nine months ended September 30,	
	2025	2024
Purchase of property, plant and equipment	$ 152,539	$ 59,273
Add: Opening balance of payable on equipment	6,491	10,127
Less: Ending balance of payable on equipment	(8,967)	(8,251)
Cash paid during the period	$ 150,063	$ 61,149

7. RELATED PARTY TRANSACTIONS

(1) Names of related parties and relationship

Names of related parties	Relationship with the Company
Daido Pharmaceutical Corporation	Note
PURE MILK CO., LTD.	Other related party (The Company is the company's institutional shareholder.)
CHUN LING INTERNATIONAL CO.,	Other related party
Vegan Joy Global Company Limited	Other related party
Corpowell B.V.	Other related party
SMY INTERNET OF PACKAGE CO., LTD.	Associate

Note: The company is no longer a related party of the Company since the company transferred its owned shares to Yong Jiang Investment Co. (which is the Company's institutional shareholder) in the second quarter of 2024.

(2) Significant related party transactions

A. Operating revenue:

	Three months ended September 30,	
	2025	2024
Sales of goods:		
Other related parties	$ 10,502	$ 3,458
Associates	-	-
	$ 10,502	$ 3,458

	Nine months ended September 30,	
	2025	2024
Sales of goods:		
Other related parties	$ 45,330	$ 8,882
Associates	-	1,268
	$ 45,330	$ 10,150

Goods are sold based on the price lists in force and terms that would be available to third parties.

B. Purchases:

	Three months ended September 30,	
	2025	2024
Purchase and processing fees:		
Other related parties	$ -	$ 35
Associates	-	-
	$ -	$ 35

	Nine months ended September 30,	
	2025	2024
Purchase and processing fees:		
Other related parties	$ -	$ 3,074
Associates	-	98
	$ -	$ 3,172

The transaction prices and payment terms to associates have no similar transactions for comparison. The payment term is 30~60 days after monthly billings.

C. Other income

	Three months ended September 30,	
	2025	2024
Rent income:		
Associates	$ -	$ -

	Nine months ended September 30,	
	2025	2024
Rent income:		
Associates	$ -	$ 37

The Company leases offices to associates. Rents are negotiated based on the mutual agreement and are collected monthly.

D. Other expenses

	Three months ended September 30,	
	2025	2024
Other expenses:		
Associates	$ 287	$ -

	Nine months ended September 30,	
	2025	2024
Other expenses:		
Associates	$ 287	$ -

Other expenses include professional services fees.

E. Receivables from related parties:

	September 30, 2025	December 31, 2024	September 30, 2024
Accounts receivable:			
Other related parties	$ 6,752	$ 48,400	$ 2,286
Associates	-	428	428
	6,752	48,828	2,714
Other receivables:			
Associates	$ 44	$ 104	$ 90
	$ 6,796	$ 48,932	$ 2,804

The receivables from related parties arise mainly from sales of goods. The receivables are due 60 to 90 days after the date of sales. The receivables are unsecured in nature and bear no interest. There are no allowances for uncollectible accounts held against receivables from related parties.

F. Payables to related parties:

	September 30, 2025	December 31, 2024	September 30, 2024
Accounts payable:			
Other related parties	$ -	$ -	$ -
Associates	-	-	152
	$ -	$ -	$ 152
Other payables:			
Other related parties	$ 287	$ -	$ -
	$ 287	$ -	$ 152

The payables to related parties arise mainly from purchase transactions and are due two months after the date of purchase. The payables bear no interest.

(3) Key management compensation

	Three months ended September 30,	
	2025	2024
Short-term employee benefits	$ 15,481	$ 16,947
Share-based payments	266	930
	$ 15,747	$ 17,877

	Nine months ended September 30,	
	2025	2024
Short-term employee benefits	$ 50,060	$ 60,631
Share-based payments	798	2,788
	$ 50,858	$ 63,419

8. PLEDGED ASSETS

The Group's assets pledged as collateral are as follows:

	Book value			
Pledged asset	September 30, 2025	December 31, 2024	September 30, 2024	Purpose
Property, plant and equipment	$ 1,392,538	$ 1,733,370	$ 1,757,461	Long-term borrowings
Current financial assets at amortized cost	28,491	5,000	5,000	Performance guarantee and customs bills negotiation
	$ 1,421,029	$ 1,738,370	$ 1,762,461	

9. SIGNIFICANT CONTINGENT LIABILITIES AND UNRECOGNIZED CONTRACT COMMITMENTS

(1) Contingencies

None.

(2) Commitments

A. Capital expenditures contracted for at the balance sheet date but not yet incurred are as follows:

	September 30, 2025	December 31, 2024	September 30, 2024
Property, plant and equipment	$ 93,526	$ 157,069	$ 150,738

B. As of September 30, 2025, December 31, 2024 and September 30, 2024, the Group's total unused letters of credit was $5,649, $2,013 and $967, respectively.

10. SIGNIFICANT DISASTER LOSS

None.

11. SIGNIFICANT EVENTS AFTER THE BALANCE SHEET DATE

None.

12. OTHERS

(1) Financial statement presentation

Certain accounts in the financial statements of the Group for the year 2024 and the third quarter of 2024 have been reclassified to ensure consistency and comparability with the financial statement presentation for the third quarter of 2025.

(2) Capital management

The Group's objectives when managing capital are based on the Group's operating industrial scale, considering the future growth of the industry and product development, setting up appropriate market share, and planning corresponding capital expenditures. Then, determining the required working capital based on the financial operation plan. Finally, taking into consideration the operating income and cash flows that can be generated by the product competitiveness to decide the appropriate capital structure.

(3) Financial instruments

A. Financial instruments by category

	September 30, 2025	December 31, 2024	September 30, 2024
Financial assets			
Financial assets at fair value through profit or loss			
Financial assets mandatorily measured at fair value through profit or loss - current	$ 13,005	$ 31,014	$ 38,832
Financial assets at fair value through other comprehensive income			
Designation of equity instrument	$ 63,525	$ 67,524	$ 62,060
Financial assets			
Financial assets at amortized cost			
Cash and cash equivalents	$ 5,504,143	$ 4,767,212	$ 4,650,147
Financial assets at amortized cost -current	263,320	865,166	670,996
Notes receivable	24,519	81,031	17,091
Accounts receivable	941,470	776,416	891,264
Accounts receivable - related parties	6,752	48,828	2,714
Other receivables	25,952	39,308	40,351
Other receivables - related parties	44	104	90
Guarantee deposits paid	22,125	37,112	38,780
	$ 6,788,325	$ 6,615,177	$ 6,311,433

	September 30, 2025	December 31, 2024	September 30, 2024
Financial liabilities			
Financial liabilities at fair value through profit or loss			
Financial liabilities held for trading	$ 1,136	$ -	$ -
Financial liabilities			
Financial liabilities at amortized cost			
Short-term borrowings	$ 1,512,520	$ 429,888	$ 504,208
Notes payable	3,897	1,518	2,874
Accounts payable	650,695	679,654	658,684
Accounts payable - related parties	-	-	152
Other accounts payable	780,150	706,381	798,445
Other accounts payable - related parties	287	-	-
Long-term borrowings (including current portion)	1,089,047	1,168,998	1,188,699
Deposits received	6,968	-	562
	$ 4,043,564	$ 2,986,439	$ 3,153,624
Lease liability	$ 171,101	$ 216,011	$ 236,192

B. Financial risk management policies

Risk management is carried out by a central treasury department (Group treasury) under policies approved by the Board of Directors. Group treasury identifies, evaluates and hedges financial risks in close co-operation with the Group's operating units. The Board provides written principles for overall risk management, as well as written policies covering specific areas and matters, such as foreign exchange risk, interest rate risk, credit risk, use of derivative financial instruments and non-derivative financial instruments, and investment of excess liquidity.

C. Significant financial risks and degrees of financial risks

(a) Market risk

Foreign exchange risk

i. The Group operates internationally and is exposed to foreign exchange risk arising from various currency exposures, primarily with respect to the USD and RMB. Foreign exchange risk arises from future commercial transactions, recognized assets and liabilities and net investments in foreign operations.

ii. The Group's businesses involve some non-functional currency operations (the Company's and certain subsidiaries' functional currency: NTD; other certain subsidiaries' functional currency: RMB). The information on assets and liabilities denominated in foreign currencies whose values would be materially affected by the exchange rate fluctuations is as follows:

		September 30, 2025		
(Foreign currency: functional currency)		Foreign currency amount (in thousands)	Exchange rate	Book value (NTD)
Financial assets				
Monetary items				
USD:NTD	USD	21,658	30.4450	$ 659,378
RMB:NTD	RMB	184,103	4.2710	786,304
EUR:NTD	EUR	6,075	35.7700	217,303
JPY:NTD	JPY	1,332,718	0.2058	274,273
Financial liabilities				
Monetary items				
JPY:NTD	JPY	404,876	0.2058	$ 83,323
RMB:NTD	RMB	163,199	4.2710	697,023
USD:NTD	USD	4,582	30.4450	139,499
EUR:NTD	EUR	943	35.7700	33,731

		December 31, 2024		
(Foreign currency: functional currency)		Foreign currency amount (in thousands)	Exchange rate	Book value (NTD)
Financial assets				
Monetary items				
USD:NTD	USD	23,542	32.7850	$ 771,824
RMB:NTD	RMB	188,875	4.4780	845,782
EUR:NTD	EUR	10,637	34.1400	363,147
JPY:NTD	JPY	959,241	0.2099	201,345
Financial liabilities				
Monetary items				
JPY:NTD	JPY	471,630	0.2099	$ 98,995
RMB:NTD	RMB	129,012	4.4780	577,716
USD:NTD	USD	4,488	32.7850	147,139
EUR:NTD	EUR	1,148	34.1400	39,193

		September 30, 2024		
(Foreign currency: functional currency)		Foreign currency amount (in thousands)	Exchange rate	Book value (NTD)
Financial assets				
Monetary items				
USD:NTD	USD	27,009	31.65	$ 854,835
RMB:NTD	RMB	200,418	4.523	906,491
EUR:NTD	EUR	6,740	35.38	238,461
JPY:NTD	JPY	659,112	0.2223	146,521
Financial liabilities				
Monetary items				
JPY:NTD	JPY	519,151	0.2223	$ 115,407
RMB:NTD	RMB	139,971	4.523	633,089
USD:NTD	USD	4,728	31.65	149,641
EUR:NTD	EUR	1,082	35.38	38,281

iii. The total exchange gain, including realized and unrealized, arising from significant foreign exchange variation on the monetary items held by the Group for the three months and nine

months ended September 30, 2025 and 2024, amounted to $23,438, ($11,494), $(31,637) and $53,878, respectively.

iv. Analysis of foreign currency market risk arising from significant foreign exchange variation:

	Nine months ended September 30, 2025		
	Sensitivity analysis		
(Foreign currency: functional currency)	Degree of variation	Effect on profit or loss	Effect on other comprehensive income
Financial assets			
Monetary items			
USD:NTD	1%	$ 6,594	$ -
RMB:NTD	"	7,863	-
EUR:NTD	"	2,173	-
JPY:NTD	"	2,743	-
Financial liabilities			
Monetary items			
JPY:NTD	1%	$ 833	$ -
RMB:NTD	"	6,970	-
USD:NTD	"	1,395	-
EUR:NTD	"	337	-

	Nine months ended September 30, 2024		
	Sensitivity analysis		
(Foreign currency: functional currency)	Degree of variation	Effect on profit or loss	Effect on other comprehensive income
Financial assets			
Monetary items			
USD:NTD	1%	$ 8,548	$ -
RMB:NTD	"	9,065	-
EUR:NTD	"	2,385	-
JPY:NTD	"	1,465	-
Financial liabilities			
Monetary items			
JPY:NTD	1%	$ 1,154	$ -
RMB:NTD	"	6,331	-
USD:NTD	"	1,496	-
EUR:NTD	"	383	-

Price risk

i. The Group's equity securities, which are exposed to price risk, are the held financial assets at fair value through profit or loss and financial assets at fair value through other comprehensive income. To manage its price risk arising from investments in equity securities, the Group diversifies its portfolio. Diversification of the portfolio is done in accordance with the limits set by the Group.

ii. The Group's investments in equity securities comprise shares issued by the domestic or foreign companies. The prices of equity securities would change due to the change of the future value of investee companies. If the prices of these equity securities had increased/decreased by 1% with all other variables held constant, profit for the nine months ended September 30, 2025 and 2024 would have increased/decreased by $119 and $388, respectively, as a result of gains/losses on equity securities classified as at fair value through profit or loss. Other components of equity would have increased/decreased by $635 and $621, respectively, as a result of other comprehensive income classified as equity investment at fair value through other comprehensive income.

Cash flow and fair value interest rate risk

i. The Group's main interest rate risk arises from long-term and short-term borrowings with variable rates, which expose the Group to cash flow interest rate risk. During the nine months ended September 30, 2025 and 2024, the Group's borrowings at variable rate were denominated in New Taiwan dollars and Chinese Renminbi.

ii. If the borrowing interest rate of New Taiwan dollars had increased/decreased by 0.1% with all other variables held constant, profit, net of tax for the nine months ended September 30 2025 and 2024 would have increased/decreased by $1,561 and $1,016, respectively. The main factor is that changes in interest expense result in floating-rate borrowings.

(b) Credit risk

i. Credit risk refers to the risk of financial loss to the Group arising from default by the clients or counterparties of financial instruments on the contract obligations. The main factor is that counterparties could not repay in full the accounts receivable based on the agreed terms, and the contract cash flows of debt instruments stated at amortized cost, at fair value through profit or loss and at fair value through other comprehensive income.

ii. The Group manages their credit risk taking into consideration the entire group's concern. For banks and financial institutions, only independently rated parties with a minimum rating of 'A' are accepted. According to the Group's credit policy, each local entity in the Group is responsible for managing and analyzing the credit risk for each of their new clients before standard payment and delivery terms and conditions are offered. Internal risk control assesses the credit quality of the customers, taking into account their financial position, past experience and other factors. Individual risk limits are set based on internal or external ratings in accordance with limits set by the Board of Directors. The utilization of credit limits is regularly monitored.

iii. The Group adopts following assumptions under IFRS 9 to assess whether there has been a significant increase in credit risk on that instrument since initial recognition:

If the contract payments were past due over 30 days based on the terms, there has been a significant increase in credit risk on that instrument since initial recognition.

iv. In accordance with the Group's credit risk management policies, the default occurs when the contract payments are past due over certain days.

v. The Group classifies customers' accounts receivable in accordance with credit risk on trade. The Group applies the modified approach using loss rate methodology to estimate expected credit loss.

vi. The Group used the forecastability to adjust historical and timely information to assess the default possibility of accounts receivable. As of September 30, 2025, December 31, 2024 and September 30, 2024, the loss rate methodology is as follows:

At September 30, 2025	Group A	Group B	Group C	Group D	Total
Expected loss rate	0%~1.44%	0%~20.23%	0%~100%	100.00%	
Total book value	$811,902	$ 167,947	$ 19,694	$ 60,964	$1,060,507
Loss allowance	$ 73	$ 20,015	$ 13,466	$ 60,964	$ 94,518

At December 31, 2024	Group A	Group B	Group C	Group D	Total
Expected loss rate	0%~1.44%	0%~20.23%	0%~100%	100.00%	
Total book value	$692,792	$ 146,155	$ 48,601	$ 67,225	$ 954,773
Loss allowance	$ 364	$ 6,401	$ 23,336	$ 67,225	$ 97,326

At September 30, 2024	Group A	Group B	Group C	Group D	Total
Expected loss rate	0%~1.44%	0%~20.23%	0%~100%	100.00%	
Total book value	$698,949	$ 146,293	$ 94,743	$ 58,929	$ 998,914
Loss allowance	$ 66	$ 3,172	$ 28,392	$ 58,929	$ 90,559

vii. Movements in relation to the Group applying the modified approach to provide loss allowance for accounts receivable are as follows:

	2025	
	Accounts receivable	Notes receivable
At January 1	$ 97,326	$ -
Reversal of impairment loss	(491)	-
Effect of foreign exchange	(2,317)	-
At September 30	$ 94,518	$ -

	2024	
	Accounts receivable	Notes receivable
At January 1	$ 67,363	$ -
Provision for impairment	22,226	-
Effect of foreign exchange	970	-
At September 30	$ 90,559	$ -

(c) Liquidity risk

i. Cash flow forecasting is performed in the operating entities of the Group and aggregated by Group treasury. Group treasury monitors rolling forecasts of the Group's liquidity requirements to ensure it has sufficient cash to meet operational needs while maintaining sufficient headroom on its undrawn committed borrowing facilities at all times so that the Group does not breach borrowing limits or covenants (where applicable) on any of its borrowing facilities. Such forecasting takes into consideration the Group's debt financing plans, covenant compliance, compliance with internal balance sheet ratio targets and, if applicable external regulatory or legal requirements.

ii. As of September 30, 2025, December 31, 2024 and September 30, 2024, the Group has undrawn borrowing facilities of $3,115,163, $5,862,445 and $8,367,314, respectively.

iii. The table below analyzes the Group's non-derivative financial liabilities into relevant maturity groupings based on the remaining period at the balance sheet date to the contractual maturity date. The amounts disclosed in the table are the contractual undiscounted cash flows.

Non-derivative financial liabilities:

September 30, 2025	Less than 1 year	Between 1 and 2 years	Between 2 and 5 years	More than 5 years
Short-term borrowings	$ 1,512,520	$ -	$ -	$ -
Notes payable	3,897	-	-	-
Accounts payable (including related parties)	650,695	-	-	-
Other payables (including related parties)	780,437	-	-	-
Lease liability	60,694	18,358	14,812	77,237
Guarantee deposits received	-	6,968	-	-
Long-term borrowings (including current portion)	80,275	-	813,273	195,499

Non-derivative financial liabilities:

December 31, 2024	Less than 1 year	Between 1 and 2 years	Between 2 and 5 years	More than 5 years
Short-term borrowings	$ 429,888	$ -	$ -	$ -
Notes payable	1,518	-	-	-
Accounts payable (including related parties)	679,654	-	-	-
Other payables (including related parties)	706,381	-	-	-
Lease liability	66,968	50,811	17,279	80,953
Long-term borrowings (including current portion)	79,469	-	752,355	337,174

Non-derivative financial liabilities:

September 30, 2024	Less than 1 year	Between 1 and 2 years	Between 2 and 5 years	More than 5 years
Short-term borrowings	$ 504,208	$ -	$ -	$ -
Notes payable	2,874	-	-	-
Accounts payable (including related parties)	658,836	-	-	-
Other payables (including related parties)	798,445	-	-	-
Lease liability	68,984	61,541	23,464	82,303
Guarantee deposits received	-	562	-	-
Long-term borrowings (including current portion)	79,203	-	758,577	350,919

(4) Fair value information

A. The different levels that the inputs to valuation techniques are used to measure fair value of financial and non-financial instruments have been defined as follows:

Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date. A market is regarded as active where a market in which transactions for the asset or liability take place with sufficient frequency and volume to provide pricing information on an ongoing basis. The fair value of the Group's investment in listed stocks is included in Level 1.

Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.

Level 3: Unobservable inputs for the asset or liability. The fair value of the Group's investment in equity investment without active market is included in Level 3.

B. Financial instruments not measured at fair value

The carrying amounts of cash and cash equivalents, notes receivable, accounts receivable, other receivables, short-term borrowings, notes payable, accounts payable and other payables are approximate to their fair values.

C. The related information of financial and non-financial instruments measured at fair value by level on the basis of the nature, characteristics and risks of the assets and liabilities is as follows:

(a) The related information of natures of the assets and liabilities is as follows:

September 30, 2025	Level 1	Level 2	Level 3	Total
Assets				
Recurring fair value measurements				
Financial assets at fair value through profit or loss				
Equity securities	$ 13,005	$ -	$ -	$ 13,005
Financial assets at fair value through other comprehensive income				
Equity securities	3,188	-	60,337	63,525
	$ 16,193	$ -	$ 60,337	$ 76,530
Liabilities				
Recurring fair value measurements				
Financial liabilities at fair value through profit or loss				
Derivative instruments	$ -	$ 1,136	$ -	$ 1,136

December 31, 2024	Level 1	Level 2	Level 3	Total
Assets				
Recurring fair value measurements				
Financial assets at fair value through profit or loss				
Equity securities	$ 31,014	$ -	$ -	$ 31,014
Financial assets at fair value through other comprehensive income				
Equity securities	3,689	-	63,835	67,524
	$ 34,703	$ -	$ 63,835	$ 98,538

September 30, 2024	Level 1	Level 2	Level 3	Total
Assets				
Recurring fair value measurements				
Financial assets at fair value through profit or loss				
Equity securities	$ 38,832	$ -	$ -	$ 38,832
Financial assets at fair value through other comprehensive income				
Equity securities	4,440	-	57,620	62,060
	$ 43,272	$ -	$ 57,620	$ 100,892

(b)The methods and assumptions the Group used to measure fair value are as follows:

i. The instruments the Group used market quoted prices as their fair values (that is, Level 1) are listed below by characteristics:

	Listed shares
Market quoted price	Closing price

ii. Except for financial instruments with active markets, the fair value of other financial instruments is measured by using valuation techniques. The fair value of financial instruments measured by using valuation techniques can be referred to current fair value of instruments with similar terms and characteristics in substance, discounted cash flow method or other valuation methods, including calculated by applying model using market information available at the consolidated balance sheet date (i.e. yield curves on the Taipei Exchange, average commercial paper interest rates quoted from Reuters).

iii. The output of valuation model is an estimated value and the valuation technique may not be able to capture all relevant factors of the Group's financial and non-financial instruments. Therefore, the estimated value derived using valuation model is adjusted accordingly with additional inputs, for example, model risk or liquidity risk and etc. In accordance with the Group's management policies and relevant control procedures relating to the valuation models used for fair value measurement, management believes adjustment to valuation is necessary in order to reasonably represent the fair value of financial and non-financial instruments at the consolidated balance sheet. The inputs and pricing information used during valuation are carefully assessed and adjusted based on current market conditions.

iv. The Group takes into account adjustments for credit risks to measure the fair value of financial and non-financial instruments to reflect credit risk of the counterparty and the Group's credit quality.

D. For the nine months ended September 30, 2025 and 2024, there was no transfer between Level 1 and Level 2.

E. The following chart is the movement of Level 3 for the nine months ended September 30, 2025 and 2024:

	Non-derivative equity instrument	
	2025	2024
At January 1	$ 63,835	$ 57,620
Gain or loss recognized in other comprehensive income	975	-
Sold in the period	(4,473)	-
At September 30	$ 60,337	$ 57,620

F. Financial segment is in charge of valuation procedures for fair value measurements being categorised within Level 3, which is to verify independent fair value of financial instruments.

Such assessment is to ensure the valuation results are reasonable by applying independent information to make results close to current market conditions, confirming the resource of information is independent, reliable and in line with other resources and represented as the exercisable price, and frequently calibrating valuation model, performing back-testing, updating inputs used to the valuation model and making any other necessary adjustments to the fair value.

G. The following is the qualitative information of significant unobservable inputs and sensitivity analysis of changes in significant unobservable inputs to valuation model used in Level 3 fair value measurement:

	Fair value at September 30, 2025	Valuation technique	Significant unobservable input	Range (weighted average)	Relationship of inputs to fair value
Non-derivative equity instrument:					
Unlisted shares	$ 60,337	Discounted cash flow	Long-term revenue growth rate	2%	The higher the long-term revenue growth rate, the higher the fair value; the higher the discount rate, the lower the fair value.
			Weighted average cost of capital	9.59%	

	Fair value at December 31, 2024	Valuation technique	Significant unobservable input	Range (weighted average)	Relationship of inputs to fair value
Non-derivative equity instrument:					
Unlisted shares	$ 63,835	Discounted cash flow	Long-term revenue growth rate	2%	The higher the long-term revenue growth rate, the higher the fair value; the higher the discount rate, the lower the fair value.
			Weighted average cost of capital	9.59%	

	Fair value at September 30, 2024	Valuation technique	Significant unobservable input	Range (weighted average)	Relationship of inputs to fair value
Non-derivative equity instrument:					
Unlisted shares	$ 57,620	Discounted cash flow	Long-term revenue growth rate	2%	The higher the long-term revenue growth rate, the higher the fair value; the higher the discount rate, the lower the fair value.
			Weighted average cost of capital	8.85%	

H. The Group has carefully assessed the valuation models and assumptions used to measure fair value. However, use of different valuation models or assumptions may result in different measurement. The following is the effect of profit or loss or of other comprehensive income from financial assets and liabilities categorised within Level 3 if the inputs used to valuation models have changed:

			September 30, 2025			
			Recognized in profit or loss		Recognized in other comprehensive income	
	Input	Change	Favourable change	Unfavourable change	Favourable change	Unfavourable change
Financial assets						
Equity instrument	Discount for lack of marketability	±5%	$ -	$ -	$ 3,017	($ 3,017)

			December 31, 2024			
			Recognized in profit or loss		Recognized in other comprehensive income	
	Input	Change	Favourable change	Unfavourable change	Favourable change	Unfavourable change
Financial assets						
Equity instrument	Discount for lack of marketability	±5%	$ -	$ -	$ 3,192	($ 3,192)

			September 30, 2024			
			Recognized in profit or loss		Recognized in other comprehensive income	
	Input	Change	Favourable change	Unfavourable change	Favourable change	Unfavourable change
Financial assets						
Equity instrument	Discount for lack of marketability	±5%	$ -	$ -	$ 2,881	($ 2,881)

13. SUPPLEMENTARY DISCLOSURES

(1) Significant transactions information

A. Loans to others: Please refer to table 1.

B. Provision of endorsements and guarantees to others: Please refer to table 2.

C. Holding of significant marketable securities at the end of the period (not including subsidiaries, associates and joint ventures): Please refer to table 3.

D. Purchases or sales of goods from or to related parties reaching $100 million or 20% of paid-in capital or more: Please refer to table 4.

E. Receivables from related parties reaching $100 million or 20% of paid-in capital or more: Please refer to table 5.

F. Significant inter-company transactions during the reporting periods: Please refer to table 6.

(2) Information on investees

Names, locations and other information of investee companies (not including investees in Mainland China): Please refer to table 7.

(3) Information on investments in Mainland China

A. Basic information: Please refer to table 8.

B. Significant transactions, either directly or indirectly through a third area, with investee companies in the Mainland Area: Please refer to table 9.

14. SEGMENT INFORMATION

(1) General information

Management has determined the reportable operating segments based on the reports reviewed by the Board of Directors that are used to make strategic decisions.

There is no material change in the basis for formation of entities and division of segments in the Group or in the measurement basis for segment information during this period.

(2) Information about segment profit or loss, assets and liabilities

The segment information provided to the Chief Operating Decision-Maker for the reportable segments is as follows:

	Taiwan	Asia	America	Other	Adjustment and reversal	Total
Nine months ended September 30, 2025						
Revenue from external customers	$ 2,929,294	$ 883,096	$ 1,079,440	$ 231,397	$ -	$ 5,123,227
Revenue from internal customers	1,173,136	164,755	259,151	-	(1,597,042)	-
Segment revenue	$ 4,102,430	$ 1,047,851	$ 1,338,591	$ 231,397	($ 1,597,042)	$ 5,123,227
Segment income (loss)	$ 870,554	$ 203,300	$ 89,313	$ 74,708	($ 502,972)	$ 734,903
Segment income (loss), including:						
Depreciation and amortization	$ 307,858	$ 67,899	$ 55,720	$ 3,537	($ 5,648)	$ 429,366
Interest income	20,435	30,276	958	-	-	51,669
Interest expense	28,195	444	6,785	50	-	35,474
Income tax expense	104,807	1,726	-	-	(6,258)	100,275
Profit (loss) of investments accounted for using equity method	163,207	45,546	(103,610)	87,084	(196,650)	(4,423)
Segment total assets	$16,183,631	$ 9,207,932	$ 1,070,978	$ 298,077	($13,203,970)	$13,556,648
Segment assets including:						
Investments accounted for using equity method	$ 4,667,378	$ 1,487,072	($ 148,644)	$ 151,798	($ 6,123,213)	$ 34,391
Capital expenditure of non-current asset	99,005	46,077	9,113	-	-	154,195
Segment total liabilities	$ 4,539,781	$ 1,229,629	$ 919,380	$ 249,138	($ 2,012,448)	$ 4,925,480

	Taiwan	Asia	America	Other	Adjustment and reversal	Total
Nine months ended September 30, 2024						
Revenue from external customers	$ 2,500,701	$ 1,527,452	$ 1,056,323	$ 209,363	$ -	$ 5,293,839
Revenue from internal customers	1,530,469	192,889	406,681	-	(2,130,039)	-
Segment revenue	$ 4,031,170	$ 1,720,341	$ 1,463,004	$ 209,363	($ 2,130,039)	$ 5,293,839
Segment income (loss)	$ 790,882	$ 317,739	$ 7,637	($ 9,727)	($ 464,278)	$ 642,253
Segment income (loss), including:						
Depreciation and amortization	$ 335,633	$ 69,151	$ 25,532	$ 25,651	($ 2,914)	$ 453,053
Interest income	20,605	30,917	262	204	-	51,988
Interest expense	26,644	690	5,588	73	-	32,995
Income tax expense	77,405	15,805	-	-	(5,662)	87,548
Profit (loss) of investments accounted for using equity method	148,357	92,926	(13,922)	9,916	(240,256)	(2,979)
Segment total assets	$15,951,157	$ 9,690,361	$ 1,351,236	$ 230,718	($13,650,779)	$13,572,693
Segment assets including:						
Investments accounted for using equity method	$ 4,614,727	$ 1,526,144	($ 53,001)	$ 43,120	($ 6,097,386)	$ 33,604
Capital expenditure of non-current asset	105,747	35,843	33,901	-	-	175,491
Segment total liabilities	$ 3,793,729	$ 1,525,867	$ 1,314,628	$ 271,340	($ 2,483,015)	$ 4,422,549

For the three months and nine months ended September 30, 2025 and 2024, sales to Europe and America of reporting department-Taiwan amounted to $167,354, $197,541, $657,609 and $565,913, respectively, and sales to Europe and America of reporting department-Asia and others amounted to $579,454, $569,930, $1,520,879 and $1,445,235, respectively.

(3) Reconciliation for segment income

Sales between segments are carried out at arm's length. The revenue from external customers reported to the Chief Operating Decision-Maker is measured in a manner consistent with that in the

statement of comprehensive income. The reportable segment income or loss is in accordance with the income before tax from continuing operations for the nine months ended September 30, 2025 and 2024. Thus, there is no reconciliation.

TCI CO., LTD. and subsidiaries

Loans to others

Nine months ended September 30, 2025

Table 1

Expressed in thousands of NTD

(Except as otherwise indicated)

No. (Note 1)	Creditor	Borrower	General ledger account (Note 2)	Is a related party	Maximum outstanding balance during the nine months ended September 30, 2025 (Note 3)	Balance at September 30, 2025	Actual amount drawn down	Interest rate	Nature of loan (Note 4 , 5)	Amount of transactions with the borrower	Reason for short-term financing	Allowance for uncollectible accounts	Collateral		Limit on loans granted to a single party	Ceiling on total loans granted	Footnote
													Item	Value			
1	TCI BIOTECH CO., LTD	TCI BIOTECH USA LLC	Other receivables - related parties	Y	$ 914,600	$ 523,198	$ 523,198	1.20%	2	$ -	For operating capital	$ -	None	$ -	$ 2,400,400	$ 2,400,400	Notes 5, 6, 7 and 8
2	TCI BIOTECH CO., LTD	TCI CO., LTD.	Other receivables - related parties	Y	1,371,900	-	-	0.00%	2	-	For operating capital	-	None	-	$ 2,400,400	$ 2,400,400	Notes 5, 6, 7 and 8

Note 1: The numbers filled in for the loans provided by the Company or subsidiaries are as follows:

(1)The Company is '0'.

(2)The subsidiaries are numbered in order starting from '1'.

Note 2: Fill in the name of account in which the loans are recognized, such as receivables–related parties, current account with stockholders, prepayments, temporary payments, etc.

Note 3: Fill in the maximum outstanding balance of loans to others during the nine months ended September 30, 2025. The amount is calculated at the closing rate of USD$1:NTD$30.4450; RMB$1:NTD$4.271, the exchange rate used in original transaction shall be adopted if there was no movement.

Note 4: For lending funds to other entities, ceiling on total loans granted by the Company's subsidiary to others is 30% of the subsidiary's net assets based on the latest financial statements, and limit on loans granted by the Company's subsidiary to a single party is 30% of the subsidiary's net assets based on the latest financial statements.

Note 5: For short-term financing with other entities, ceiling on total loans granted by the Company's subsidiary to others is 30% of the subsidiary's net assets based on the latest financial statements, and limit on loans granted by the Company's subsidiary to a single party is 30% of the subsidiary's net assets based on the latest financial statements.

Note 6: For lending funds or short-term financing with other entities, ceiling on total loans granted by the Company's subsidiary to others is 40% of the subsidiary's net assets based on the latest financial statements, and limit on loans granted by the Company's subsidiary to a single party is 30% of the subsidiary's net assets based on the latest financial statements.

Note 7: Non-Taiwan companies that directly and indirectly hold 100% of the voting shares of the same ultimate parent company as our company , or the ultimate parent company that directly and indirectly holds 100% of the voting shares is not subject to the restrictions of Notes 4, 5, and 6 when engaging in fund lending. The total amount of loans and the limit of loans to a single enterprise must not exceed the loan limit. It is limited to 100% of the net worth of the enterprise.

Note 8: The amounts were approved by the Board of Directors.

TCI CO., LTD. and subsidiaries

Provision of endorsements and guarantees to others

Nine months ended September 30, 2025

Table 2

Expressed in thousands of NTD

(Except as otherwise indicated)

No. (Note 1)	Endorser/ guarantor	Party being endorsed/guaranteed: Company name	Party being endorsed/guaranteed: Relationship with the endorser/ guarantor (Note 2)	Limit on endorsements/ guarantees provided for a single party	Maximum outstanding endorsement/ guarantee amount	Outstanding endorsement/ guarantee amount	Actual amount drawn down	Amount of endorsements/ guarantees secured with collateral	Ratio of accumulated endorsement/ guarantee amount to net asset value of the endorser/ guarantor company (%)	Ceiling on total amount of endorsements/ guarantees provided	Provision of endorsements/ guarantees by parent company to subsidiary (Note 4)	Provision of endorsements/ guarantees by subsidiary to parent company (Note 4)	Provision of endorsements/ guarantees to the party in Mainland China (Note 4)	Footnote
0	TCI CO., LTD.	TCI BIOTECH LLC	2	$ 1,457,976	$ 16,603	$ 15,223	$ 15,223	$ -	0.21	$ 3,644,940	Y	N	N	Note 3
0	TCI CO., LTD.	TCI BIOTECH USA LLC	2	$ 1,457,976	149,423	137,002	137,002	-	1.88	$ 3,644,940	Y	N	N	Note 3

Note 1: The numbers filled in for the loans provided by the Company or subsidiaries are as follows:

(1) The Company is '0'.

(2) The subsidiaries are numbered in order starting from '1'.

Note 2: Relationship between the endorser/guarantor and the party being endorsed/guaranteed is classified into the following seven categories:

(1) Having business relationship.

(2) The endorser/guarantor parent company owns directly and indirectly more than 50% voting shares of the endorsed/guaranteed subsidiary.

(3) The endorsed/guaranteed company owns directly and indirectly more than 50% voting shares of the endorser/guarantor parent company.

(4)The endorser/guarantor parent company owns directly and indirectly more than 50% voting shares of the endorsed/guaranteed company.

(5) Mutual guarantee of the trade made by the endorsed/guaranteed company or joint contractor as required under the construction contract.

(6) Due to joint venture, all shareholders provide endorsements/guarantees to the endorsed/guaranteed company in proportion to its ownership.

(7) Joint guarantee of the performance guarantee for pre-sold home sales contract as required under the Consumer Protection Act.

Note 3: In accordance with the Company's policy, the total guarantee amount shall not exceed 50% of Company's net assets based on the latest financial statements, and the guarantee to a single party shall not exceed 20% of the Company's net assets.

Note 4: Amount of endorsements/guarantees between the endorsed/guaranteed companies whose voting shares are more 90% held by the Company directly or/and indirectly shall not exceed 10% of the Company's net assets, except the amount of endordements/guarantees between the endorsed/guaranteed companies whose voting shares are 100% held by the Company directly and indirectly.

Note 5: In accordance with the Company and subsidiaris's policy, the guarantee shall not exceed 50% of the Company's net assets based on the latest financial statements.

Note 6: In accordance with the Company and subsidiaris's policy, the guarantee to a single party shall not exceed 30% of the Company's net assets based on the latest financial statements.

Note 7: For endorsements and guarantees made due to business transactions, the endorsement and guarantee amount shall not exceed the amount of business transactions between the parties in the most recent year. The term "business transaction amount" refers to the higher of the purchase or sales amount between the parties.

Note 8: The subsidiaries and parent companies referred to in these Measures shall be identified in accordance with Financial Reporting Standards of the securities issuer.

Note 9: The financial report is prepared in accordance with the International Financial Reporting Standards, and the term "net value" refers to the equity attributable to the owner of the parent company on the balance sheet stipulated in the Financial Reporting Standards of the securities issuer.

TCI CO., LTD.

Holding of marketable securities at the end of the period (not including subsidiaries, associates and joint ventures)

Nine months ended September 30, 2025

Table 3

Expressed in thousands of NTD

(Except as otherwise indicated)

Securities held by	Marketable securities	Relationship with the securities issuer	General ledger account	As of September 30, 2025				Footnote
				Number of shares	Book value	Ownership (%)	Fair value	
TCI CO., LTD.	BILLION ELECTRIC CO., LTD.	None	Financial assets at fair value through other comprehensive income - non-current	125,039	$ 3,189	0.11	$ 3,189	
TCI CO., LTD.	LIN LIE INTEGRATION CO., LTD.	None	Financial assets at fair value through other comprehensive income - non-current	54,000	372	3.48	372	
TCI CO., LTD.	PURE MILK CO., LTD.	The Company was an institutional shareholder of PURE MILK CO., LTD..	Financial assets at fair value through other comprehensive income - non-current	321,333	7,786	7.30	7,786	
TCI LIVING CO., LTD.	Chun Ling International Co., Ltd.	None	Financial assets at fair value through other comprehensive income - non-current	774,046	52,178	18.42	52,178	
GENE & NEXT INC.	TCI CO., LTD.	Parent company	Financial assets at fair value through other comprehensive income - current	3,653,000	429,228	3.10	429,228	
MAXIGEN BIOTECH INC.	TCI CO., LTD.	Parent company	Financial assets at fair value through other comprehensive income - non-current	2,531,000	297,392	2.58	297,392	
TCI CO., LTD.	Abnova Holding Corporation	None	Financial assets at fair value through profit or loss-current	509,000	13,005	0.84	13,005	
GENE & NEXT INC.	TCI CO., LTD.	Parent company	Financial assets at fair value through profit or loss-current	1,362,000	160,035	1.16	160,035	

TCI CO., LTD. and subsidiaries

Purchases or sales of goods from or to related parties reaching NT$100 million or 20% of paid-in capital or more

Nine months ended September 30, 2025

Table 4

Expressed in thousands of NTD

(Except as otherwise indicated)

			Transaction				Differences in transaction terms compared to third party transactions		Notes/accounts receivable (payable)		
Purchaser/seller	Counterparty	Relationship with the counterparty	Purchases (sales)	Amount	Percentage of total purchases (sales)	Credit term	Unit price	Credit term	Balance	Percentage of total notes/accounts receivable (payable)	Footnote
TCI CO., LTD.	TCI BIOTECH CO., LTD	Subsidiary	(Sales)	$ 261,406	(7.96)	60-90 days	The prices and terms of sales and purchases are available to third parties.	Terms for collections are approximately the same as those with third parties.	$ 13,373	1.37	
TCI CO., LTD.	TCI BIOTECH LLC	Subsidiary	(Sales)	501,865	(15.29)	60-90 days	The prices and terms of sales and purchases are available to third parties.	Terms for collections are approximately the same as those with third parties.	72,625	7.46	
TCI CO., LTD.	TCI BIOTECH NETHERLANDS B.V.	Subsidiary	(Sales)	180,930	(5.51)	60-90 days	The prices and terms of sales and purchases are available to third parties.	Terms for collections are approximately the same as those with third parties.	210,070	21.58	
TCI BIOTECH USA LLC	TCI BIOTECH LLC	Subsidiary	(Sales)	258,538	(91.00)	60-90 days	The prices and terms of sales and purchases are available to third parties.	Terms for collections are approximately the same as those with third parties.	33,513	72.32	
TCI International Trading Co., Ltd	TCI CO., LTD.	Subsidiary	(Sales)	108,600	(76.16)	60-90 days	The prices and terms of sales and purchases are available to third parties.	Terms for collections are approximately the same as those with third parties.	96,869	95.25	
TCI BIOTECH LLC	TCI CO., LTD.	Subsidiary	Purchases	501,865	47.92	60-90 days	The prices and terms of sales and purchases are available to third parties.	Terms for collections are approximately the same as those with third parties.	72,625	64.79	
TCI BIOTECH CO., LTD	TCI CO., LTD.	Subsidiary	Purchases	261,406	53.85	60-90 days	The prices and terms of sales and purchases are available to third parties.	Terms for collections are approximately the same as those with third parties.	13,373	9.25	
TCI BIOTECH LLC	TCI BIOTECH USA LLC	Subsidiary	Purchases	258,538	24.69	60-90 days	The prices and terms of sales and purchases are available to third parties.	Terms for collections are approximately the same as those with third parties.	33,513	29.90	
TCI CO., LTD.	TCI International Trading Co., Ltd	Subsidiary	Purchases	108,600	7.73	60-90 days	The prices and terms of sales and purchases are available to third parties.	Terms for collections are approximately the same as those with third parties.	96,869	15.73	
TCI BIOTECH NETHERLANDS B.V.	TCI CO., LTD.	Subsidiary	Purchases	108,930	108.57	60-90 days	The prices and terms of sales and purchases are available to third parties.	Terms for collections are approximately the same as those with third parties.	210,070	105.06	

Note: Regarding percentage of transaction amount to total operating revenues or total assets, it is computed based on period-end balance of transaction to total assets for balance sheet accounts and based on accumulated transaction amount for the period to total operating revenues for income statement accounts.

TCI CO., LTD. and subsidiaries

Receivables from related parties reaching NT$100 million or 20% of paid-in capital or more

Nine months ended September 30, 2025

Table 5

Expressed in thousands of NTD

(Except as otherwise indicated)

Creditor	Counterparty	Relationship with the counterparty		Balance as at September 30, 2025	Turnover rate	Overdue receivables		Amount collected subsequent to the balance sheet date	Allowance for doubtful accounts
						Amount	Action taken		
TCI CO., LTD.	TCI BIOTECH NETHERLANDS B.V.	Subsidiary	Accounts receivable	$ 210,070	1.20 times	$ 142,842	Repay according to the mutual	$ -	-

TCI CO., LTD. and subsidiaries

Significant inter-company transactions during the reporting periods

Nine months ended September 30, 2025

Table 6

Expressed in thousands of NTD

(Except as otherwise indicated)

Number (Note 1)	Company name	Counterparty	Relationship (Note 2)	Transaction			
				General ledger account	Amount	Transaction terms	Percentage of consolidated total operating revenues or total assets (Note 3)
0	TCI CO., LTD.	TCI BIOTECH CO., LTD	1	Sales of goods	$ 261,406	The prices and terms of sales and purchases are available to third parties.	5.10
0	TCI CO., LTD.	TCI BIOTECH NETHERLANDS B.V.	1	Sales of goods	180,930	The prices and terms of sales and purchases are available to third parties.	3.53
0	TCI CO., LTD.	TCI BIOTECH NETHERLANDS B.V.	1	Accounts receivable	210,070	The prices and terms of sales and purchases are available to third parties.	1.55
0	TCI CO., LTD.	TCI BIOTECH LLC	1	Sales of goods	501,865	The prices and terms of sales and purchases are available to third parties.	9.80
0	TCI CO., LTD.	TCI International Trading Co., Ltd	1	Cost of goods sold	108,600	The prices and terms of sales and purchases are available to third parties.	2.12
1	TCI BIOTECH USA LLC	TCI BIOTECH LLC	2	Sales of goods	258,538	The prices and terms of sales and purchases are available to third parties.	5.05
2	TCI BIOTECH LLC	TCI CO., LTD.	2	Cost of goods sold	501,865	The prices and terms of sales and purchases are available to third parties.	9.80
2	TCI BIOTECH LLC	TCI BIOTECH USA LLC	2	Cost of goods sold	258,538	The prices and terms of sales and purchases are available to third parties.	5.05
3	TCI BIOTECH CO., LTD	TCI CO., LTD.	2	Cost of goods sold	261,406	The prices and terms of sales and purchases are available to third parties.	5.10
3	TCI BIOTECH CO., LTD	TCI BIOTECH USA LLC	3	Other receivables	523,198	According to the mutually agreed terms and conditions of the loan.	3.86
4	TCI International Trading Co., Ltd	TCI CO., LTD.	2	Sales of goods	108,600	The prices and terms of sales and purchases are available to third parties.	2.12
5	TCI BIOTECH NETHERLANDS B.V.	TCI CO., LTD.	2	Cost of goods sold	180,930	The prices and terms of sales and purchases are available to third parties.	3.53
5	TCI BIOTECH NETHERLANDS B.V.	TCI CO., LTD.	2	Accounts payable	210,070	The prices and terms of sales and purchases are available to third parties.	1.55

Note 1: The numbers filled in for the transaction company in respect of inter-company transactions are as follows:

(1) Parent company is '0'.

(2) The subsidiaries are numbered in order starting from '1'.

Note 2: Relationship between transaction company and counterparty is classified into the following three categories :

(1) Parent company to subsidiary.

(2) Subsidiary to parent company.

(3) Subsidiary to subsidiary.

Note 3: Regarding percentage of transaction amount to total operating revenues or total assets, it is computed based on period-end balance of transaction to total assets for balance sheet accounts and based on accumulated transaction amount for the period to total operating revenues for income statement accounts.

TCI CO., LTD.and subsidiaries

Information on investees

Nine months ended September 30, 2025

Table 7

Expressed in thousands of NTD

(Except as otherwise indicated)

Investor	Investee	Location	Main business activities	Initial investment amount		Shares held as at September 30, 2025			Net profit (loss) of the investee for the nine months ended September 30, 2025	Investment income (loss) recognized by the Company for the nine months ended September 30, 2025	Footnote
				Balance as at September 30, 2025	Balance as at December 31, 2024	Number of shares	Ownership (%)	Book value			
TCI CO., LTD.	TCI FIRSTEK CORP.	Taiwan	Wholesale and retail of health foods and cosmetics	$ 43,685	$ 43,685	214,885,489	100.00	$ 2,806,429	$ 40,562	$ 40,562	None
TCI CO., LTD.	GENE & NEXT INC.	Taiwan	Research and development of biotechnology and genetics	37,079	37,079	11,173,692	42.23	147,753	50,815	24,381	None
TCI CO., LTD.	TCI HK LIMITED	Hong Kong	Trading health foods and cosmetics	21,046	21,046	-	100.00	19,930	(2,118)	(2,118)	None
TCI CO., LTD.	TCI BIOTECH LLC	U.S.A.	Trading health foods and cosmetics	8,778	8,778	300	3.85	5,831	89,313	3,435	None
TCI CO., LTD.	BIOCOSME CO., LTD.	Taiwan	Trading health foods and cosmetics	5,000	5,000	500,000	100.00	5,094	18	18	None
TCI CO., LTD.	TCI JAPAN CO., LTD.	JAPAN	Trading health foods and cosmetics	15,626	15,626	5,500	100.00	(697)	(43)	(43)	None
TCI CO., LTD.	PT TCI BIOTEK INDO	Indonesia	Trading health foods and cosmetics	17,635	17,635	89,000	100.00	13,017	(1,505)	(1,505)	None
TCI CO., LTD.	TCI BIOTECH NETHERLANDS B.V.	Netherlands	Trading health foods and cosmetics	210,955	210,955	6,592,950	100.00	48,939	74,708	74,708	None
TCI CO., LTD.	SMY INTERENT OF PACKAGE CO., LTD.	Taiwan	Producing, manufacturing and selling of packaging containers	1,900	1,900	190,000	15.39	3,690	(2,129)	(328)	None
TCI CO., LTD.	QUANTUM BIOLOGY INC.	Taiwan	Research and development of biotechnology	30,000	30,000	3,000,000	100.00	6,512	(508)	(508)	None
TCI CO., LTD.	MAXIGEN BIOTECH INC.	Taiwan	Wholesale of cosmetics and research and development, producing and sales of biologicals	826,198	679,748	25,347,762	28.26	719,674	181,570	41,976	None
TCI CO., LTD.	VEGAN JOY GLOBAL COMPANY LIMITED	Taiwan	Wholesale and retail of food, grocery and beverage	3,800	3,800	380,000	19.00	-	(8,357)	-	None
TCI CO., LTD.	WAN LIN LLC	Taiwan	Wholesale and retail of food, grocery and beverage	-	1,140	-	0.00	-	(124)	(24)	None
TCI CO., LTD.	AYURGA INDIA PRIVATE LIMITED	India	Trading health foods and cosmetics	9,209	-	26,000,000	100.00	8,819	(106)	(106)	Note 3
TCI BIOTECH NETHERLANDS B.V.	TCI BIOTECH LLC	U.S.A	Trading health foods and cosmetics	207,588	207,588	7,500	96.15	145,756	89,313	85,878	None
TCI BIOTECH NETHERLANDS B.V.	Corpowell B.V.	Belgium	Trading health foods and cosmetics	5,207	5,207	25	25.00	6,037	4,823	1,206	None
TCI BIOTECH LLC	TCI BIOTECH USA LLC	U.S.A	Producing and manufacturing health foods and cosmetics	207,588	207,588	7,500	100.00	(148,638)	(103,610)	(103,610)	None

TCI CO., LTD.and subsidiaries

Information on investees

Nine months ended September 30, 2025

Table 7

Expressed in thousands of NTD

(Except as otherwise indicated)

Investor	Investee	Location	Main business activities	Initial investment amount		Shares held as at September 30, 2025			Net profit (loss) of the investee for the nine months ended September 30, 2025	Investment income (loss) recognized by the Company for the nine months ended September 30, 2025	Footnote
				Balance as at September 30, 2025	Balance as at December 31, 2024	Number of shares	Ownership (%)	Book value			
GENE & NEXT INC.	GLUX HK LIMITED	Hong Kong	Trading health foods and cosmetics	$ 29,542	$ 29,542	-	100.00	$ 271	$ -	$ -	None
GENE & NEXT INC.	TCI LIVING CO., LTD.	Taiwan	Trading health foods and cosmetics	43,175	43,175	4,023,254	79.31	83,341	(8,011)	(6,354)	None
GENE & NEXT INC.	ASIA PATHOGENOMIC CO., LTD.	Taiwan	Wholesale of chemical industrial and medical devices	49,050	34,200	2,740,000	16.75	22,638	(30,381)	(5,167)	None
TCI LIVING CO., LTD.	TCI LIVING (HK) LIMITED	Hong Kong	Trading health foods and cosmetics	5,847	5,847	-	100.00	2,997	(5)	(5)	None

Note 1: If a public company is equipped with an overseas holding company and takes consolidated financial report as the main financial report according to the local law rules, it can only disclose the information of the overseas holding company about the disclosure of related overseas investee information.

Note 2: If situation does not belong to Note 1, fill in the columns according to the following regulations:

(1)The columns of 'Investee', 'Location', 'Main business activities', Initial investment amount' and 'Shares held as at September 30, 2025' should fill orderly in the Company's (public company's) information on investees and every directly or indirectly controlled investee's investment information, and note the relationship between the Company (public company) and its investee each (ex. direct subsidiary or indirect subsidiary) in the 'footnote' column.

(2)The 'Net profit (loss) of the investee for the nine months ended September 30, 2025' column should fill in amount of net profit (loss) of the investee for this period.

(3)The 'Investment income (loss) recognized by the Company for the nine months ended September 30, 2025' column should fill in the Company (public company) recognized investment income (loss) of its direct subsidiary and recognized investment income (loss) of its investee accounted for under the equity method for this period. When filling in recognized investment income (loss) of its direct subsidiary, the Company (public company) should confirm that direct subsidiary's net profit (loss) for this period has included its investment income (loss) which shall be recognized by regulations.

Note 3: The company injected capital of $9,209 on June 1, 2025.

TCI CO., LTD. and subsidiaries

Information on investments in Mainland China

Nine months ended September 30, 2025

Table 8

Expressed in thousands of NTD

(Except as otherwise indicated)

Investee in Mainland China	Main business activities	Paid-in capital	Investment method	Accumulated amount of remittance from Taiwan to Mainland China as of January 1, 2025	Amount remitted from Taiwan to Mainland China/ Amount remitted back to Taiwan for the nine months ended September 30, 2025		Accumulated amount of remittance from Taiwan to Mainland China as of September 30, 2025	Net income (loss) of investee as of September 30, 2025	Ownership held by the Company (direct or indirect)	Investment income (loss) recognized by the Company for the nine months ended September 30, 2025	Book value of investments in Mainland China as of September 30, 2025	Accumulated amount of investment income remitted back to Taiwan as of September 30, 2025	Footnote
					Remitted to Mainland China	Remitted back to Taiwan							
TCI International Trading Co., Ltd	Wholesale of health foods, cosmetics and chemical productions; cosmetic manufacturing	$ 14,117	Note 3	$ 15,440	$ -	$ -	$ 15,440	$ 40,561	100.00	$ 40,561	$ 2,858,104	$ 1,383,547	Note 5 Note 6
SHANGHAI BIOSCIENCE CO., LTD.	Wholesale of health foods, cosmetics and chemical productions; cosmetics manufacturing	26,064	Note 2	-	-	-	-	39,597	100.00	39,597	2,491,203	-	Note 5 Note 6
SHANGHAI BIOCOSME CO., LTD.	Producing cosmetics	143,352	Note 2	-	-	-	-	53,057	100.00	1,018	196,075	-	Note 5 Note 6
TCI BIOTECH CO., LTD	Producing health foods	1,131,425	Note 1	438,307	-	-	438,307	42,369	100.00	42,369	2,400,400	942,055	Note 5 Note 6
TCI LIVING SHANGHAI CO., LTD.	Trading health foods and cosmetics	8,916	Note 3	8,916	-	-	8,916	(155)	79.31	(123)	922	-	Note 5 Note 6
Maxigen Biotech Shanghai Co., Ltd.	Sales of medical machinery and comestics	US$1,800	Note 3	58,193	-	-	58,193	(22,696)	100.00	(22,696)	(93,016)	-	Note 5 Note 6
Shanghai Kaiaosi Technology Co., Ltd.	Sales of health food and cosmetics	10,061	Note 2	-	-	-	-	(599)	18.40	(110)	2,026	-	Note 5 Note 6

Note 1：Reinvestments in a company in Mainland China through parent company in Taiwan and SHANGHAI BIOSCIENCE CO., LTD. (USD$14,400 and RMB$168,700)
Note 2：Reinvestments in a company in Mainland China through TCI International Trading Co., Ltd.
Note 3：Reinvestments in a company in Mainland China through domestic subsidiary company.
Note 4：Reinvestments in a company in Mainland China through SHANGHAI BIOSCIENCE CO., LTD.
Note 5：The amount recognized was based on the financial statements that were reviewed by R.O.C. parent company's CPA firm.

Company name	Accumulated amount of remittance from Taiwan to Mainland China as of September 30, 2025	Investment amount approved by the Investment Commission of the Ministry of Economic Affairs (MOEA)	Ceiling on investments in Mainland China imposed by the Investment Commission of MOEA(Note 7)
TCI CO., LTD.	$ 438,307	$ 692,000	$ 5,178,701
TCI FIRSTEK CORP.	15,440	15,440	1,718,108
MAXIGEN BIOTECH INC.	58,193	54,801	884,132
TCI LIVING CO., LTD.	8,916	31,484	61,940

Note 6：The numbers in this table are expressed in New Taiwan dollars, except for: assets and liabilities presented at RMB$1：NTD$4.2710, USD$1：NTD$30.4450 ; income presented at RMB$1：NTD$4.3111, USD$1：NTD$31.1547;
Note 7：The amount is the higher of limits on accumulated investment amounts or 60% of consolidated net assets was based on Investment Commission, MOEA Regulation No. 09704604680 announced on August 29, 2008.

TCI CO., LTD. and subsidiaries

Significant transactions , either directly or indirectly through a third area, with investee companies in the Mainland Area

Nine months ended September 30, 2025

Table 9

Expressed in thousands of NTD

(Except as otherwise indicated)

Investee in Mainland China	Sale (purchase)		Property transaction		Accounts receivable (payable)		Provision of endorsements/guarantees or collaterals		Financing				
	Amount	%	Amount	%	Balance at September 30, 2025	%	Balance at September 30, 2025	Purpose	Maximum balance during the nine months ended September 30, 2025	Balance at September 30, 2025	Interest rate	Interest during the nine months ended September 30, 2025	Others
TCI BIOTECH CO., LTD	$ 261,406	7.96	-	-	$ 13,373	1.37	-	-	-	-	-	-	
TCI International Trading Co., Ltd	108,600	7.73	-	-	(96,869)	15.73	-	-	-	-	-	-	

Note: Regarding percentage of transaction amount to total operating revenues or total assets, it is computed based on period-end balance of transaction to total assets for balance sheet accounts and based on accumulated transaction amount for the period to consolidated total operating revenues for income statement accounts.